Livongo Health (LVGO) 10-Q 10 Aug 20 2020 Q2 Quarterly report Financial data

COVER PAGE

COVER PAGE - shares shares in Thousands	6 Months Ended
	Jun. 30, 2020	Jul. 31, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2020
Document Transition Report	false
Entity File Number	001-38983
Entity Registrant Name	Livongo Health, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-3542036
Entity Address, Address Line One	150 West Evelyn Avenue
Entity Address, Address Line Two	Suite 150
Entity Address, City or Town	Mountain View
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94041
City Area Code	866
Local Phone Number	435-5643
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	LVGO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		100,308
Entity Central Index Key	0001639225
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 685,953	$ 241,738
Short-term investments	150,000	150,000
Accounts receivable, net of allowance for doubtful accounts of $2,774 and $1,245 as of June 30, 2020 and December 31, 2019, respectively	59,237	40,875
Inventories	17,616	28,983
Deferred costs, current	27,137	16,051
Prepaid expenses and other current assets	11,318	9,860
Total current assets	951,261	487,507
Property and equipment, net	16,209	10,354
Operating lease right-of-use assets	16,253	0
Restricted cash, noncurrent	1,270	1,270
Goodwill	35,801	35,801
Intangible assets, net	15,081	16,469
Deferred costs, noncurrent	12,843	5,700
Other noncurrent assets	569	3,460
TOTAL ASSETS	1,049,287	560,561
Current liabilities:
Accounts payable	6,401	8,362
Accrued expenses and other current liabilities	35,684	27,801
Deferred revenue, current	5,420	3,945
Advance payments from partner, current	354	1,767
Total current liabilities	47,859	41,875
Operating lease liabilities, noncurrent	15,758	0
Deferred revenue, noncurrent	1,561	654
Advance payment from partner, noncurrent	9,142	7,754
Convertible senior notes, net	396,446	0
Other noncurrent liabilities	397	2,914
Total Liabilities	471,163	53,197
Stockholders’ equity:
Preferred stock, par value of $0.001 per share; 100,000 shares authorized as of June 30, 2020 and December 31, 2019, respectively; zero shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	0	0
Common stock, par value of $0.001 per share; 900,000 shares authorized as of June 30, 2020 and December 31, 2019, respectively; 99,412 and 95,301 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	100	95
Additional paid-in capital	749,349	671,467
Accumulated deficit	(171,325)	(164,198)
TOTAL STOCKHOLDERS’ EQUITY	578,124	507,364
TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ EQUITY	$ 1,049,287	$ 560,561
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	100,000,000	100,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	900,000,000	900,000,000

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Allowance for doubtful accounts	$ 2,774	$ 1,245
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	100,000,000	100,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	900,000,000	900,000,000
Common stock, shares issued (in shares)	99,412,000
Common stock, shares outstanding (in shares)	99,412,000	95,301,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenue	$ 91,923	$ 40,915	$ 160,745	$ 72,982
Cost of revenue	21,466	11,964	39,572	21,827
Gross profit	70,457	28,951	121,173	51,155
Operating expenses:
Research and development	15,809	10,291	29,806	19,285
Sales and marketing	32,881	17,833	60,535	32,476
General and administrative	22,027	13,702	37,874	27,816
Change in fair value of contingent consideration	2	282	86	956
Total operating expenses	70,719	42,108	128,301	80,533
Loss from operations	(262)	(13,157)	(7,128)	(29,378)
Interest income	1,099	183	2,476	641
Interest expense	(2,283)	0	(2,320)	0
Other (expense) income, net	(36)	2	(62)	6
Loss before provision for income taxes	(1,482)	(12,972)	(7,034)	(28,731)
Provision for (benefit from) income taxes	72	5	93	(1,383)
Net loss	(1,554)	(12,977)	(7,127)	(27,348)
Accretion of redeemable convertible preferred stock	0	(42)	0	(83)
Net loss attributable to common stockholders	$ (1,554)	$ (13,019)	$ (7,127)	$ (27,431)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.02)	$ (0.69)	$ (0.07)	$ (1.48)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares)	97,896	18,916	96,719	18,564

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) (unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated DeficitCumulative Effect, Period of Adoption, Adjustment	Restricted stock unitsCommon Stock	Restricted Stock Awards	Restricted Stock AwardsCommon Stock	Restricted Stock AwardsAdditional Paid-in Capital
Redeemable convertible preferred stock, shares outstanding at of beginning period (in shares) at Dec. 31, 2018	58,615
Redeemable convertible preferred stock, outstanding at beginning of period at Dec. 31, 2018	$ 236,929
Temporary Equity
Accretion of redeemable convertible preferred stock	$ 83
Redeemable convertible preferred stock, shares outstanding at end of period (in shares) at Jun. 30, 2019	58,615
Redeemable convertible preferred stock, outstanding at end of period at Jun. 30, 2019	$ 237,012
Common stock, shares outstanding at beginning of period (in shares) at Dec. 31, 2018			17,691
Stockholders' equity (deficit) at beginning of period at Dec. 31, 2018	(91,806)	$ 4,685	$ 18	$ 21,789	$ (113,613)	$ 4,685
Stockholders' Equity
Accretion of redeemable convertible preferred stock	(83)			(83)
Issuance of common stock upon exercise of stock options (in shares)			3,199
Issuance of common stock upon exercise of stock options	1,443		$ 2	1,441
Issuance of stock awards	0							$ 0	$ 1	$ (1)
Stock-based compensation expense	10,180			10,180
Net loss	(27,348)				(27,348)
Common stock, shares outstanding at end of period (in shares) at Jun. 30, 2019			20,890
Stockholders' equity (deficit) at end of period at Jun. 30, 2019	$ (102,929)		$ 21	33,326	(136,276)
Redeemable convertible preferred stock, shares outstanding at of beginning period (in shares) at Mar. 31, 2019	58,615
Redeemable convertible preferred stock, outstanding at beginning of period at Mar. 31, 2019	$ 236,970
Temporary Equity
Accretion of redeemable convertible preferred stock	$ 42
Redeemable convertible preferred stock, shares outstanding at end of period (in shares) at Jun. 30, 2019	58,615
Redeemable convertible preferred stock, outstanding at end of period at Jun. 30, 2019	$ 237,012
Common stock, shares outstanding at beginning of period (in shares) at Mar. 31, 2019			19,618
Stockholders' equity (deficit) at beginning of period at Mar. 31, 2019	(95,693)		$ 20	27,586	(123,299)
Stockholders' Equity
Accretion of redeemable convertible preferred stock	(42)			(42)
Issuance of common stock upon exercise of stock options (in shares)			1,272
Issuance of common stock upon exercise of stock options	1,129		$ 1	1,128
Stock-based compensation expense	4,654			4,654
Net loss	(12,977)				(12,977)
Common stock, shares outstanding at end of period (in shares) at Jun. 30, 2019			20,890
Stockholders' equity (deficit) at end of period at Jun. 30, 2019	$ (102,929)		$ 21	33,326	(136,276)
Redeemable convertible preferred stock, shares outstanding at of beginning period (in shares) at Dec. 31, 2019	0
Redeemable convertible preferred stock, outstanding at beginning of period at Dec. 31, 2019	$ 0
Temporary Equity
Accretion of redeemable convertible preferred stock	$ 0
Redeemable convertible preferred stock, shares outstanding at end of period (in shares) at Jun. 30, 2020	0
Redeemable convertible preferred stock, outstanding at end of period at Jun. 30, 2020	$ 0
Common stock, shares outstanding at beginning of period (in shares) at Dec. 31, 2019			95,301
Stockholders' equity (deficit) at beginning of period at Dec. 31, 2019	$ 507,364		$ 95	671,467	(164,198)
Stockholders' Equity
Issuance of common stock upon exercise of stock options (in shares)	2,837		2,837
Issuance of common stock upon exercise of stock options	$ 3,846		$ 3	3,843
Issuance of stock awards (in shares)							1,676
Issuance of stock awards	0		$ 1	(1)
Tax withholding on releasing of restricted stock units (in shares)			(493)
Tax withholding on releasing of stock awards	(16,762)			(16,762)
Issuance of common stock ESPP purchase (in shares)			91
Issuance of common stock ESPP Purchase	2,155		$ 1	2,154
Equity component of the convertible senior notes	144,106			144,106
Equity component of the issuance costs	(4,036)			(4,036)
Purchase of capped call related to convertible senior notes	(69,850)			(69,850)
Stock-based compensation expense	18,428			18,428
Net loss	(7,127)				(7,127)
Common stock, shares outstanding at end of period (in shares) at Jun. 30, 2020			99,412
Stockholders' equity (deficit) at end of period at Jun. 30, 2020	$ 578,124		$ 100	749,349	(171,325)
Stockholders' Equity
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201602Member
Redeemable convertible preferred stock, shares outstanding at of beginning period (in shares) at Mar. 31, 2020	0
Redeemable convertible preferred stock, outstanding at beginning of period at Mar. 31, 2020	$ 0
Temporary Equity
Accretion of redeemable convertible preferred stock	$ 0
Redeemable convertible preferred stock, shares outstanding at end of period (in shares) at Jun. 30, 2020	0
Redeemable convertible preferred stock, outstanding at end of period at Jun. 30, 2020	$ 0
Common stock, shares outstanding at beginning of period (in shares) at Mar. 31, 2020			97,293
Stockholders' equity (deficit) at beginning of period at Mar. 31, 2020	501,288		$ 97	670,962	(169,771)
Stockholders' Equity
Issuance of common stock upon exercise of stock options (in shares)			1,590
Issuance of common stock upon exercise of stock options	2,124		$ 2	2,122
Issuance of stock awards (in shares)							556
Issuance of stock awards	0
Tax withholding on releasing of restricted stock units (in shares)			(118)
Tax withholding on releasing of stock awards	(6,198)			(6,198)
Issuance of common stock ESPP purchase (in shares)			91
Issuance of common stock ESPP Purchase	2,155		$ 1	2,154
Equity component of the convertible senior notes	144,106			144,106
Equity component of the issuance costs	(4,036)			(4,036)
Purchase of capped call related to convertible senior notes	(69,850)			(69,850)
Stock-based compensation expense	10,089			10,089
Net loss	(1,554)				(1,554)
Common stock, shares outstanding at end of period (in shares) at Jun. 30, 2020			99,412
Stockholders' equity (deficit) at end of period at Jun. 30, 2020	$ 578,124		$ 100	$ 749,349	$ (171,325)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (7,127)	$ (27,348)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	2,619	1,450
Amortization of intangible assets	1,388	1,193
Non-cash operating lease cost	2,199	0
Amortization of debt discount and debt issuance cost	1,922	0
Change in fair value of contingent consideration	86	956
Allowance for doubtful accounts	1,644	511
Stock-based compensation expense	17,938	9,963
Deferred income taxes	0	(1,396)
Changes in operating assets and liabilities, net of impact of acquisitions:
Accounts receivable, net	(20,006)	(17,637)
Inventories	11,367	(4,901)
Deferred costs	(18,035)	(7,781)
Prepaid expenses and other assets	(667)	(205)
Accounts payable	(2,626)	2,257
Accrued expenses and other liabilities	3,399	(48)
Operating lease liabilities	(83)	0
Deferred revenue	2,382	653
Advance payments from partner	0	2,372
Net cash used in operating activities	(3,600)	(39,961)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(4,476)	(628)
Capitalized internal-use software costs	(2,780)	(2,378)
Change in escrow deposit	2,100	1,750
Investment in certificate of deposit	(50,000)	0
Proceeds from maturity of certificate of deposit	50,000	0
Acquisitions, net of cash acquired	0	(27,435)
Net cash used in investing activities	(5,156)	(28,691)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of stock options, net of repurchases	3,846	1,443
Proceeds from issuance of common stock under employee stock purchase plan	2,154	0
Payment of deferred offering costs	(286)	(1,559)
Payment of deferred acquisition-related contingent consideration	(1,356)	(1,316)
Proceeds from issuance of convertible notes, net of transaction costs of $14,775	535,225	0
Payment of capped calls related to issuance of convertible senior notes	(69,850)	0
Taxes paid related to net share settlement of equity awards	(16,762)	0
Net cash provided by (used in) financing activities	452,971	(1,432)
Net increase (decrease) in cash, cash equivalents, and restricted cash	444,215	(70,084)
Cash, cash equivalents, and restricted cash, beginning of period	243,008	109,107
Cash, cash equivalents, and restricted cash, end of period	687,223	39,023
Reconciliation of cash, cash equivalents, and restricted cash:
Cash and cash equivalents	685,953	38,165
Restricted cash	1,270	858
Total cash, cash equivalents, and restricted cash, end of period	687,223	39,023
SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Accretion of redeemable convertible preferred stock	0	83
Purchases of property and equipment included in accounts payable and accrued liabilities	1,256	87
Contingent consideration liability related to myStrength acquisition	0	3,300
Unpaid working capital adjustment related to myStrength acquisition	0	119
Capitalized internal-use software costs in accounts payable and accrued liabilities	(335)	(61)
Convertible senior notes issuance costs in accounts payable and accrued liabilities	631	0
Unpaid offering costs	$ 0	$ 1,312

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parenthetical) $ in Thousands	Jun. 30, 2020USD ($)
Statement of Cash Flows [Abstract]
Issuance costs	$ 14,775

Organization and Description of

Organization and Description of Business	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business Nature of the Business Livongo Health, Inc. (“we”, “us”, “the Company”, or “Livongo”) was incorporated in the state of Delaware on October 16, 2008, under the name of EosHealth, Inc. In September 2014, we changed our name to Livongo Health, Inc. Livongo empowers people with chronic conditions to live better and healthier lives. We have created a unified platform that provides smart, cellular-connected devices, supplies, informed coaching, data science-enabled insights and facilitates access to medications across multiple chronic conditions to help our members lead better lives. We currently offer Livongo for Diabetes, Livongo for Hypertension, Livongo for Prediabetes and Weight Management, and Livongo for Behavioral Health by myStrength. We create consumer-first experiences with high member satisfaction, measurable, sustainable health outcomes, and more cost-effective care for our members and our clients. This approach is leading to better clinical and financial outcomes while also creating a better experience for people with chronic conditions and their care team of family, friends, and medical professionals. Our headquarters are located in Mountain View, California, and we serve customers throughout North America. Initial Public Offering In July 2019, we completed our initial public offering ("IPO") in which we issued and sold 14,590,050 shares of our common stock at an offering price of $28.00 per share, including 1,903,050 shares of common stock pursuant to the exercise in full of the underwriters' option to purchase additional shares. We received net proceeds of $377.5 million, after deducting underwriting discounts and commissions of $28.6 million and offering costs of $2.4 million. Offering costs were capitalized and consisted of fees and expenses incurred in connection with the sale of our common stock in the IPO, including the legal, accounting, printing and other IPO-related costs. Upon completion of the IPO, these deferred offering costs were reclassified to stockholders’ equity and recorded against the proceeds from the offering. Immediately prior to the closing of the IPO, all 58,615,488 shares of our then-outstanding redeemable convertible preferred stock automatically converted into 58,615,488 shares of common stock at their respective conversion ratios and we reclassified $236.9 million of redeemable convertible preferred stock to additional paid-in capital and $0.1 million to common stock on our condensed consolidated balance sheet. Reverse Stock Split In June 2019, our board of directors and stockholders approved a 1-for-2 reverse stock split of our common stock and redeemable convertible preferred stock, which was effected on June 27, 2019 pursuant to an amendment to our amended and restated certificate of incorporation. The par value of the common stock and redeemable convertible preferred stock was not adjusted as a result of the reverse stock split. All references to redeemable convertible preferred stock, common stock, options to purchase common stock, restricted stock awards, restricted stock units, common stock warrants, per share data, and related information included in the accompanying condensed consolidated financial statements have been adjusted to reflect this reverse stock split for all periods presented. Liquidity and Capital Resources We have incurred losses since inception. As of June 30, 2020, we had an accumulated deficit of $171.3 million. During the six months ended June 30, 2020, we incurred a net loss of $7.1 million and used $3.6 million of cash in operating activities. During the six months ended June 30, 2019, we incurred a net loss of $27.3 million and used $40.0 million of cash in operating activities. As described above, we received net proceeds of $377.5 million from our IPO in July 2019. Prior to our IPO, we primarily funded our operations through the sale of our redeemable convertible preferred stock. In addition, in June 2020, and as more fully described in Note 3, we raised additional financing through the issuance of $550.0 million aggregate principle of 0.875% convertible senior notes due 2025 (the "Notes"). The continued execution of our long-term business plan may require us to explore additional financing. While we have historically been successful in obtaining both equity and debt financing, there can be no assurance that such additional financing, if necessary, will be available or, if available, that such financings can be obtained on satisfactory terms.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of Livongo Health, Inc. and our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated. The condensed consolidated balance sheet as of December 31, 2019 included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by U.S. GAAP. The accompanying interim condensed consolidated balance sheets as of June 30, 2020, the interim condensed consolidated statements of operations and the interim condensed consolidated statements of redeemable convertible preferred stock and stockholders’ deficit for the three and six months ended June 30, 2020 and 2019, and the interim condensed consolidated statements of cash flows for the six months ended June 30, 2020 and 2019 are unaudited. These interim condensed consolidated financial statements have been prepared on a basis consistent with the annual consolidated financial statements and, in the opinion of management, include all adjustments necessary to fairly state our financial position as of June 30, 2020, the results of our operations for the three and six months ended June 30, 2020 and 2019 and result of our cash flows for the six months ended June 30, 2020 and 2019. The financial data and other financial information disclosure in the notes to these interim condensed consolidated financial statements related to the three and six months periods are also unaudited. The results for the three and six months ended June 30, 2020 are not necessarily indicative of the operating results expected for the year ending December 31, 2020 or any future period. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related footnotes included in our latest annual report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 24, 2020. We have revised our condensed consolidated statements of operations and cash flows for the three and six months ended June 30, 2019 to reflect the adoption of Accounting Standards Update ("ASU") No. 2014-09 We made other adjustments to our financial results for the first quarter through the third quarter of 2019 to correct errors that consist of (i) a $1.9 million total adjustment for the capitalization and amortization of device costs for Livongo for Hypertension and Livongo for Prediabetes and Weight Management, (ii) a $1.2 million total reduction of sales and marketing expenses for the capitalization and amortization of certain sales commissions, and (iii) a $0.4 million increase in sales and marketing expenses. We evaluated the materiality of these revisions, quantitatively and qualitatively, and determined that these revisions were not material to any of our previously issued condensed consolidated financial statements. In addition, in connection with the preparation of our 2019 Annual Report on Form 10-K, we identified an immaterial error in the condensed consolidated statements of cash flows for the second and third quarterly periods of 2019 included in our 2019 Quarterly Reports on Form 10-Q relating to the release of an escrow deposit for a prior acquisition that was incorrectly classified as a cash outflow within investing activities. We have corrected the error in the accompanying six months ended June 30, 2019 condensed consolidated statement of cash flows by decreasing cash flows used in investing activities by $1.3 million and increasing cash flows used in financing activities by $1.3 million. Comprehensive Loss For the three and six months ended June 30, 2020 and 2019, there was no difference between comprehensive loss and net loss. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the financial statements, as well as the reported amounts of revenue and expenses during the periods presented. Such estimates, judgments, and assumptions include: revenue recognition, allowance for doubtful accounts, the period of benefit for deferred commissions, the period of benefit for deferred device costs, estimated costs for capitalized internal-use software, assessment of the useful life and recoverability of long-lived assets, fair values of stock-based awards, contingent consideration in business combinations, the incremental borrowing rate ("IBR") applied in lease accounting, effective interest rate of the liability component of our Notes, income taxes, and fair value of Notes. Actual results could be different from these estimates. While the COVID-19 pandemic has not had a material adverse impact on our results of operations to date, our estimates for revenue recognition and allowance for doubtful accounts, as well as our other estimates, judgments, and assumptions, may be materially and adversely different from our actual results as a result of the COVID-19 pandemic. To the extent there are material differences between these estimates, judgments, or assumptions and actual results, our financial statements will be affected. Convertible Senior Notes On June 4, 2020 (“Issuance Date”), we issued $550.0 million aggregate principal amount of 0.875% Convertible Senior Notes due 2025 ("Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Each $1,000 of principal of these Notes is initially convertible into 13.2329 shares of our common stock, which is equivalent to an initial conversion price of approximately $75.57 per share, subject to adjustment upon the occurrence of specified events set forth in the indenture that governs the terms of the Notes (the "Indenture"). The Notes are general unsecured obligations of Livongo and interest is payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020. The Notes will mature on June 1, 2025, unless earlier converted, redeemed or repurchased. The total net proceeds from the offering were $534.6 million after deducting purchasing discounts and issuance costs, of which $0.6 million was paid subsequent to June 30, 2020. See Note 3 for additional details. The Notes are accounted for in accordance with FASB ASC Subtopic 470-20, Debt with Conversion and Other Options. Pursuant to ASC Subtopic 470-20, issuers of certain convertible debt instruments, such as the Notes, that have a net settlement feature and may be settled wholly or partially in cash upon conversion are required to separately account for the liability (debt) and equity (conversion option) components of the instrument. The carrying amount of the liability component of the instrument is computed by estimating the fair value of a similar liability without the conversion option using an income-based approach. For the income-based approach, we use a convertible bond lattice model that includes assumptions such as volatility and the risk-free rate. The amount of the equity component is then calculated by deducting the fair value of the liability component from the principal amount of the Notes. The difference between the principal amount and the liability component represents a debt discount that is amortized to interest expense over the contractual term of the Notes using an effective interest rate method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. In accounting for the issuance costs related to the Notes, the allocation of issuance costs incurred between the liability and equity components were based on their relative values. Emerging Growth Company Status We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period and, as a result, we may not adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies until required by private company accounting standards. Concentration of Risk Financial instruments that potentially subject us to credit risk consist principally of cash, cash equivalents, certificates of deposit, accounts receivable and the Capped Call Transactions (Note 3). We maintain our cash primarily with domestic financial institutions of high credit quality, which may exceed federal deposit insurance corporation limits. We invest our cash equivalents in highly rated money market funds and short-term investments in certificates of deposit. We have not experienced any losses in such accounts. We believe we are not exposed to any significant credit risk on cash, cash equivalents, investments and restricted cash and perform periodic evaluations of the credit standing of such institutions. Our sales are predominately to self-insured employers, healthcare providers, and insurance carriers located throughout North America. Accounts receivable are recorded at the invoiced amount, and are stated at realizable value, net of an allowance for doubtful accounts. We perform ongoing assessments of our clients to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with clients. We have not experienced material credit losses from our accounts receivable. Significant clients and partners are those which represent 10% or more of our net accounts receivable balance or revenue during the period at each respective consolidated balance sheet date. There were no clients that represented 10% or more of our revenue or accounts receivable balance for the three and six months ended June 30, 2019 or as of December 31, 2019. For each significant client that represented 10% or more of our accounts receivable balance or revenue during the three and six months ended June 30, 2020, revenue as a percentage of total revenue and accounts receivable as a percentage of net accounts receivable were as follows: Revenue Accounts Receivable Three Months Ended June 30, Six Months Ended June 30, June 30, December 31, 2020 2019 2020 2019 2020 2019 (unaudited) Client A 25 % — % 21 — % 12 % — % Our significant client was contracted through a partner, which is not shown below as the only revenue and our accounts receivable balance for such significant partner is from our significant client. For each significant partner that represented 10% or more of our accounts receivable balance or revenue during the periods presented, revenue as a percentage of total revenue and accounts receivable as a percentage of net accounts receivable were as follows: Revenue Accounts Receivable Three Months Ended June 30, Six Months Ended June 30, June 30, December 31, 2020 2019 2020 2019 2020 2019 (unaudited) Partner A 17 % 27 % 20 % 26 % 17 % 23 % Partner B 15 % 24 % 16 24 % 21 % 25 % We utilize a limited number of manufacturing vendors to build and assemble our products. The hardware components included in our devices are sourced from various suppliers by the manufacturer and are principally industry standard parts and components that are available from multiple vendors. Device quality or performance failures or changes in the contractors’ or vendors’ financial or business condition could disrupt our ability to supply quality products to our clients and thereby have a material adverse impact on our business, financial condition and results of operations. Recent Accounting Pronouncements Adopted in Fiscal 2020 Leases: In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-02 Leases (Topic 842) and subsequent amendments to the initial guidance (collectively, "ASC 842"), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. This ASU is effective for us for the interim periods and year ending December 31, 2020. Early adoption is permitted. We adopted ASC 842 on January 1, 2020 using the modified retrospective approach by electing to use the optional transition method which allows us to continue to apply the previous guidance, including disclosure requirements, in the comparative periods presented. We elected to use certain practical expedients permitted under the transition guidance within the new guidance, which allows us to carry forward the historical accounting relating to lease identification and classification for existing leases upon adoption. We also elected not to use the hindsight practical expedient in determining the lease term and impairment of the operating lease right-of-use ("ROU") assets and elected not to record operating leases with an initial term of 12 months or less on our condensed consolidated balance sheets. We elected not to separate lease and non-lease components for all classes of underlying assets. Adoption of the new lease standard resulted in the recording of ROU assets and operating lease liabilities of approximately $18.1 million and $18.6 million, respectively, as of January 1, 2020. The difference between the ROU assets and operating lease liabilities primarily relates to deferred rent of $0.5 million recorded in accordance with the previous lease guidance. The adoption had no impact on total cash flows from operations other than a change within operating cash flows. We determine if an arrangement is or contains a lease at inception. Our lease agreements do not contain any material options to extend or terminate leases, any material residual value guarantees, any material restrictions or covenants, or any material variable lease payments. Any variable lease payments consist of common area maintenance, taxes and other costs and are expensed as incurred. We have performed an evaluation of our other contracts with customers and suppliers in accordance with ASC 842 and have determined that, none of our other contracts contain a lease. ROU assets represent our right to use an underlying asset for the lease term, while operating lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. In determining the present value of lease payments, we use our IBR based on the information available at the lease commencement date, including the lease term, for operating leases. The incremental borrowing rate is a hypothetical rate based on our understanding of what our credit rating would be for a secured borrowing in the country where the lease was executed. Upon adoption, the ROU asset was valued at the amount of the operating lease liabilities adjusted for lease incentives, prepaid rent, and deferred rent as of January 1, 2020. The adoption of the new standard resulted in changes to our accounting policies for leases and in additional disclosures. See Note 8. Stock-Based Compensation: In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting . The standard simplifies the accounting for share-based payments granted to nonemployees for goods and services and aligns most of the guidance on such payments to the nonemployees with the requirements for share-based payments granted to employees. ASU No. 2018-07 is effective for us for the interim periods and the year beginning January 1, 2020. Early adoption is permitted. We adopted this new standard using a prospective method on January 1, 2020. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. Disclosure of Fair Value Measurement: In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of the FASB's disclosure framework project. The new standard is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including interim reporting periods within those fiscal years. ASU 2018-13 is effective for us for the interim periods and the year beginning January 1, 2020. We adopted the new standard using a prospective method effective on January 1, 2020. The adoption of this ASU resulted in additional disclosures in Note 7 of our condensed consolidated financial statements. Cloud Computing Arrangements Implementation Costs : In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use-software. This ASU is effective for us for the year ending December 31, 2021, and interim periods within the year ending December 31, 2022. Early adoption is permitted. We early adopted this new standard on a prospective method effective on April 1, 2020, which did not have a material impact on the Company's condensed consolidated financial statements. New Accounting Pronouncements Not Yet Adopted Credit Losses: In June 2018, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . The standard requires a financial asset measured at amortized cost basis to be presented at the net amount expected to be collected, with further clarifications made more recently. For trade receivables, loans, and other financial assets, we will be required to use a forward-looking expected loss model rather than the incurred loss model for recognizing credit losses which reflects losses that are probable. Credit losses relating to available-for-sale debt securities are required to be recorded through an allowance for credit losses rather than a reduction in the amortized cost basis of the securities. This new standard is effective for us for the interim periods within and the year ending December 31, 2020. Early adoption is permitted. We are currently evaluating the impact of this ASU on our consolidated financial statements. Income Taxes : In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which simplifies that accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amending existing guidance to improve consistent application. This new standard is effective for our interim periods within and year ending December 31, 2021. Early adoption is permitted. Most amendments within this standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements.

Debt

Debt	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Debt	Debt Convertible Senior Notes On June 4, 2020 (“Issuance Date”), we issued $550.0 million aggregate principal amount of Notes in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Each $1,000 of principal of these Notes is initially convertible into 13.2329 shares of our common stock, which is equivalent to an initial conversion price of approximately $75.57 per share, subject to adjustment upon the occurrence of specified events set forth in the Indenture. The Notes are general unsecured obligations of Livongo and interest is payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020. The Notes will mature on June 1, 2025, unless earlier converted, redeemed or repurchased. The total net proceeds from the offering were $534.6 million after deducting purchasing discounts and issuance costs, of which 0.6 million was paid subsequent to June 30, 2020. Holders of the Notes may convert their Notes at their option at any time prior to the close of business on the business day immediately preceding March 1, 2025, only under the following circumstances: (1) during any fiscal quarter commencing after the fiscal quarter ending on September 30, 2020 (and only during such fiscal quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five-business day period after any five consecutive trading day period (the ‘‘measurement period’’) in which the trading price (as defined in the Indenture) per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the Notes on each such trading day; (3) if we call such Notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after March 1, 2025, holders may convert all or any portion of their Notes at any time prior to the close of business on the scheduled trading day immediately preceding the maturity date regardless of the foregoing conditions. Upon conversion, it is our current intent to settle the first $1,000 of conversion value for each $1,000 principal amount of the Notes in cash and pay or deliver cash, shares of common stock or a combination of cash and shares of common stock for any remaining conversion value in excess of the principal amount, in each case at our election. If we satisfy our conversion obligation solely in cash or through payment and delivery of a combination of cash and shares of common stock the amount of cash and shares of common stock, if any, due upon conversion will be based on a daily conversion value calculated on a proportionate basis for each trading day in a 40 - trading day observation period. If we undergo a fundamental change (as defined in the Indenture) at any time prior to the maturity date, holders will have the right, at their option, to require us to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, following certain corporate events that occur prior to the maturity date or following our issuance of a notice of redemption, we will increase the conversion rate for a holder who elects to convert its Notes in connection with such a corporate event or convert its Notes called for redemption during the related redemption period in certain circumstances. We may not redeem the Notes prior to June 5, 2023. On or after June 5, 2023 and prior to the 41st scheduled trading day immediately preceding the maturity date, we may redeem for cash all or any portion of the Notes, at our option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. Total issuance costs of $15.4 million related to the Notes were allocated between liability and equity in the relative values as the allocation of the total proceeds to the liability and equity components. Issuance costs attributable to the liability component are being amortized to interest expense over the contractual term of the Notes based on the effective interest rate. The issuance costs attributable to the equity component were netted against the respective equity component in Additional paid-in capital. We recorded liability issuance costs of $11.4 million and equity issuance costs of $4.0 million. The carrying value of the Notes consisted of the following (in thousands): As of June 30, 2020 Liability component: Principal $ 550,000 Less: unamortized discount (142,324) Less: unamortized issuance costs (11,230) Net carrying amount $ 396,446 Equity component: Notes $ 144,106 Less: issuance costs (4,036) Carrying amount of the equity component (1) $ 140,070 (1) Included in the consolidated balance sheets within Additional paid-in capital. As of June 30, 2020, the fair value of the Notes was $660 million. The fair value of the Notes was determined on the basis of market prices observable for similar instruments and is considered Level 2 in the fair value hierarchy. We carry the liability component of the Notes at face value less unamortized debt discount and issuance costs on our condensed consolidated balance sheets and provide the fair value for disclosure purposes only. Total interest expense on the Notes, reflecting the effective interest rate of 7.72%, was as follows for the three and six months ended June 30, 2020 (in thousands): Three and six months ended June 30, 2020 Contractual interest expense $ 361 Amortization of debt discount 1,781 Amortization of issuance costs 141 Total $ 2,283 The following table summarizes the payments due by period for the Notes. Payments Due by Period Less than 1 Year 1-3 Years 3-5 Years More than 5 Years Total (in thousands) Payment of principal and interest of convertible senior notes $ 4,772 $ 9,625 $ 559,625 $ — $ 574,022 Capped Call Transactions In connection with the issuance of the Notes, we entered into privately negotiated capped call transactions (the "Capped Call Transactions") with certain of the initial purchasers of the Notes and/or their respective affiliates or other financial institutions (the “counterparties”). The Capped Call Transactions give us the right to purchase 7.3 million shares at a strike price equal to $75.57 per share, subject to certain adjustments, corresponding with the conversion rate and conversion price of the Notes, respectively. The Capped Call Transactions will be net share or net cash settled, at our option, subject to a stock market price cap of $118.54. The Capped Call Transactions are expected to partially offset the potential dilution to our common stock upon conversion of the Notes and/or offset any cash payments we are required to make in excess of the principal amount upon conversion of the Notes to the extent that the market price per share of our common stock, as measured under the terms of the Capped Call Transactions, is greater than the strike price of the Capped Call Transactions and less than the cap price of the Capped Call Transaction. We paid $69.9 million to the counterparties for the cost of the Capped Call Transactions. Final settlement of the Capped Call Transactions is scheduled to occur on May 29, 2025, however they could be exercised and settled early upon the occurrence of certain events as set forth in the Indenture or in connection with the conversion, redemption, or repurchase of a corresponding Note. The cost of $69.9 million incurred to purchase the Capped Call Transactions is recorded as a reduction to our additional paid-in capital and will not be remeasured. Revolving Loan In July 2019, we entered into a Loan and Security Agreement with Silicon Valley Bank ("SVB"). The agreement provides a secured revolving loan facility in an aggregate principal amount of up to $30.0 million with a maturity of any revolving loan thereunder in July 2022. Revolving loans under this facility bear interest at a floating rate equal to the greater of (i) 5.25% or (ii) the prime rate published in the Wall Street Journal, minus 0.25%. Interest on any revolving loan is due and payable monthly in arrears. Our obligations under the Loan and Security Agreement are secured by a security interest on substantially all of our assets, excluding our intellectual property. The Loan and Security Agreement contains a financial covenant along with covenants limiting our ability to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock, and make investments, in each case subject to certain exceptions. The Loan and Security Agreement also contains customary events of default, upon which SVB may declare all or a portion of our outstanding obligations payable to be immediately due and payable. There were no amounts outstanding under the agreement as of June 30, 2020 or December 31, 2019. Fees incurred under the revolving loan facility during the three months ended June 30, 2020 were not material. The Loan and Security Agreement was amended on June 1, 2020 to, among other things, permit the issuance of the Notes and the entry into the Capped Call Transactions.

Revenue, Deferred Revenue, and

Revenue, Deferred Revenue, and Deferred Costs and Other	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue, Deferred Revenue and Deferred Costs and Other	Revenue, Deferred Revenue and Deferred Costs and Other Deferred Revenue Deferred revenue activity is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2020 2019 2020 2019 Balance at beginning of period $ 6,099 $ 3,527 $ 4,599 $ 2,051 Amounts billed but unrecognized 2,937 2,390 6,077 3,768 Revenue recognized (2,055) (1,813) (3,695) (3,122) Assumed from business combination — — — 1,407 Balance at end of period $ 6,981 $ 4,104 $ 6,981 $ 4,104 Balance at the end of period (in thousands): June 30, June 30, 2020 2019 Deferred revenue, current $ 5,420 $ 3,467 Deferred revenue, noncurrent 1,561 637 Total deferred revenue $ 6,981 $ 4,104 We expect to recognize $5.4 million of revenue in the next 12 months and $1.6 million of revenue thereafter, related to future performance obligations that were unsatisfied or partially satisfied as of June 30, 2020. Accrued Rebates Accrued rebates represent the amounts in client contracts that are subject to pricing adjustments based on various performance metrics, such as member satisfaction scores, cost savings guarantees and health outcome guarantees, which if not met typically require us to refund a portion of the per participant per month fee paid. We defer an estimate of the amount of consideration that we expect to refund to our clients from the monthly per participant per month fee until the performance metric is met. As of June 30, 2020 and December 31, 2019, accrued rebates of $1.6 million and $1.2 million, respectively, were recorded within accrued expenses and other current liabilities on our condensed consolidated balance sheets. The activity is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2020 2019 2020 2019 Balance at beginning of period $ 1,730 $ 533 $ 1,152 $ 609 ASC 606 adoption date impact adjustment — — — (222) Amount deferred 398 (9) 1,174 184 Revenue recognized (275) — (473) (2) Payments (211) (50) (211) (95) Balance at end of period $ 1,642 $ 474 $ 1,642 $ 474 Deferred Costs and Other Deferred costs and other activity are as follows (in thousands): Three Months Ended June 30, 2020 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Balance at beginning of period $ 29,750 $ 2,868 $ 472 $ 33,090 Additions 14,606 80 96 14,782 Revenue recognized — — (167) (167) Cost of revenue recognized (7,430) — — (7,430) Sales and marketing expenses recognized — (294) — (294) Balance at end of period $ 36,926 $ 2,654 $ 401 $ 39,981 Three Months Ended June 30, 2019 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Balance at beginning of period $ 14,366 $ 3,438 $ 638 $ 18,442 Additions 6,095 184 32 6,311 Revenue recognized — — (250) (250) Cost of revenue recognized (3,350) — — (3,350) Sales and marketing expenses recognized — (257) — (257) Balance at end of period $ 17,111 $ 3,365 $ 420 $ 20,896 Six Months Ended June 30, 2020 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Balance at beginning of period $ 18,579 $ 2,988 $ 184 $ 21,751 Additions 31,750 254 514 32,518 Revenue recognized — — (297) (297) Cost of revenue recognized (13,403) — — (13,403) Sales and marketing expenses recognized — (588) — (588) Balance at end of period $ 36,926 $ 2,654 $ 401 $ 39,981 Six Months Ended June 30, 2019 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Balance at beginning of period $ 8,469 $ — $ — $ 8,469 ASC 606 adoption date impact adjustment — 3,692 771 4,463 Additions 14,590 184 144 14,918 Revenue recognized — — (495) (495) Cost of revenue recognized (5,948) — — (5,948) Sales and marketing expenses recognized $ — $ (511) $ — $ (511) Balance at end of period $ 17,111 $ 3,365 $ 420 $ 20,896 Balance at the end of period (in thousands): June 30, 2020 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Deferred costs, current $ 25,561 $ 1,176 $ 401 $ 27,138 Deferred costs, noncurrent 11,365 1,478 — 12,843 Total deferred costs $ 36,926 $ 2,654 $ 401 $ 39,981 December 31, 2019 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Deferred costs, current $ 14,746 $ 1,121 $ 184 $ 16,051 Deferred costs, noncurrent 3,833 1,867 — 5,700 Total deferred costs $ 18,579 $ 2,988 $ 184 $ 21,751

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Business Combinations	Business Combinations Retrofit Inc. We acquired all of the issued and outstanding shares of Retrofit Inc. (“Retrofit”), a privately-held, Illinois-based entity, and a leading provider of weight-management and disease-prevention programs, through a share purchase agreement (the “Retrofit Purchase Agreement”) in exchange for cash consideration (the “Retrofit Acquisition”) in April 2018. The Retrofit Acquisition provides us with an evidence-based diabetes prevention program that enhances our data science capabilities and our expertise in holistic weight management including nutrition, exercise and mindset. The total consideration transferred as part of the Retrofit Acquisition consisted of a cash payment on the closing date, adjusted for customary closing adjustments, of $12.4 million. Upon the close of the Retrofit Acquisition, as part of the Retrofit Purchase Agreement, we placed in escrow an earn-out consideration of $7.0 million held by a third-party escrow agent to be released to the former stockholders of Retrofit contingent upon achieving future qualified member targets as determined on December 31, 2019, 2020, and 2021 (the “Retrofit Contingent Consideration”). We recorded a corresponding escrow asset of $7.0 million on our condensed consolidated balance sheet upon the close of the acquisition. We estimated the fair value of the Retrofit Contingent Consideration to be $6.2 million as of the acquisition date using a Monte Carlo simulation model, which together with the cash consideration resulted in total purchase consideration of $18.6 million. The Retrofit Contingent Consideration is subject to remeasurement at each reporting date until the payments are released from escrow, with the remeasurement adjustment reported in our condensed consolidated statements of operations. During the three and six months ended June 30, 2019, the fair value of the Retrofit Contingent Consideration had reduced and we recorded a benefit of $0.3 million and such amounts were insignificant for the three and six months ended June 30, 2020, In April 2019, we released $1.8 million from the escrow deposit, of which $1.3 million was paid to the former stockholders of Retrofit and in June 2020, we released $2.1 million, of which $0.5 million was paid to the former stockholders of Retrofit. As of June 30, 2020 and December 31, 2019, the remaining Retrofit Contingent Consideration was $2.4 million and $2.8 million, respectively. myStrength, Inc. In February 2019, we acquired all of the issued and outstanding shares of myStrength, Inc. (“myStrength”), a privately-held entity based in Denver, Colorado, and a leading provider of digital behavioral health solutions through an agreement and plan of merger (the “myStrength Purchase Agreement”) in exchange for cash consideration (the “myStrength Acquisition”). The myStrength Acquisition has enabled us to more fully address the health of the whole person by bringing behavioral health conditions including depression, anxiety, stress, substance use disorder, chronic pain, opioid addiction and recovery, and insomnia to our Applied Health Signals solution. The total consideration for the myStrength Acquisition was $30.1 million in cash, subject to a closing adjustment of $0.1 million. As part of the myStrength Purchase Agreement, we are obligated to pay an earn-out consideration up to $5.0 million contingent upon satisfying future milestones for the year ended December 31, 2019 (the “myStrength Contingent Consideration”). We estimated the fair value of the myStrength Contingent Consideration to be $3.3 million as of the acquisition date using a Monte Carlo simulation model, which together with the cash consideration, resulted in total purchase consideration of $33.5 million. The myStrength Contingent Consideration was subject to remeasurement at each reporting date until the payments are made, with the remeasurement adjustment reported in our condensed consolidated statements of operations. For the three and six months ended June 30, 2019, we increased the fair value of the myStrength Contingent Consideration and recorded an expense of $0.6 and $1.2 million, respectively, in our condensed consolidated statements of operations. In December 2019, we paid $2.4 million of the myStrength contingent consideration to the former shareholders of myStrength. In February 2020, we paid the remaining fair value of the myStrength contingent consideration of $2.6 million. The purchase consideration of $33.5 million was allocated as follows: Amount (in thousands) Cash and cash equivalents $ 2,643 Accounts receivable 1,337 Other current assets 140 Property and equipment 114 Intangible assets 13,900 Other assets 34 Total assets acquired 18,168 Accounts payable 173 Accrued expenses and other liabilities 1,787 Deferred revenue 1,407 Deferred tax liability, net 1,396 Total liabilities assumed 4,763 Goodwill 20,092 Total purchase consideration $ 33,497 The following table sets forth the components of the identifiable intangible assets acquired and their estimated useful lives as of the acquisition date: Cost Useful Life (in thousands) (years) Customer relationships $ 4,300 7.0 Developed technology 9,200 7.0 Trade name 400 5.0 Total $ 13,900 The estimated fair values of the intangible assets acquired were determined based on the income approach to measure the fair value of the trade name, customer relationships, and developed technology. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. Additionally, in the first quarter of 2019, we incurred a total of $0.2 million of acquisition-related costs as a result of the myStrength acquisition. Goodwill represents the excess of the purchase consideration over the estimated acquisition date fair value of the net tangible and intangible assets acquired and liabilities assumed. Goodwill is primarily attributable to expected post-acquisition synergies from integrating myStrength’s assembled workforce and developed technology into our product offerings and cross-selling opportunities. Goodwill recorded is not deductible for income tax purposes. The results of operations of myStrength have been included in our consolidated financial statements from the respective date of purchase. Unaudited Pro Forma Financial Information The following unaudited pro forma information presents the combined results of operations as if the myStrength Acquisition had been completed on January 1, 2018, the beginning of the comparable prior annual reporting period. The unaudited pro forma results include adjustments primarily related to the following: (i) interest expense related to the legacy debt of myStrength that was not acquired; (ii) amortization of the acquired intangible assets; (iii) fair value adjustment for deferred revenue; (iv) the inclusion of acquisition-related costs as of the earliest period presented; and (v) the associated tax impact of the acquisitions and these unaudited pro forma adjustments. Six Months Ended June 30, 2019 (in thousands) Revenue $ 73,580 Net loss $ (26,009)

Balance Sheet Components

Balance Sheet Components	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components Inventories Inventories of $17.6 million and $29.0 million, as of June 30, 2020 and December 31, 2019, respectively, consisted of finished goods. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: June 30, December 31, 2020 2019 (in thousands) Prepaid expenses $ 5,821 $ 6,691 Escrow deposit, current 3,244 2,100 Interest receivable 1,118 504 Prepaid rent 568 352 Short-term deposits 567 201 Other current assets — 12 Total $ 11,318 $ 9,860 Property and Equipment, Net Property and equipment consisted of the following: June 30, December 31, 2020 2019 (in thousands) Computer, equipment and software $ 4,618 $ 2,218 Furniture and fixtures 1,971 915 Capitalized internal-use software 13,971 11,229 Leasehold improvements 3,207 1,092 Property and equipment 23,767 15,454 Less: accumulated depreciation (7,558) (5,100) Property and equipment, net $ 16,209 $ 10,354 Depreciation and amortization expense was $1.4 million and $0.7 million for the three months ended June 30, 2020 and 2019, respectively, and $2.6 million and $1.5 million for the six months ended June 30, 2020 and 2019, respectively. Intangible Assets, Net Intangible assets consisted of the following as of June 30, 2020: Gross Value Accumulated Net Book Weighted- (in thousands) (years) Customer relationships $ 8,190 $ (1,729) $ 6,461 6.6 Developed technology 11,020 (2,687) 8,333 5.2 Trade name 448 (161) 287 3.6 Total $ 19,658 $ (4,577) $ 15,081 Intangible assets consisted of the following as of December 31, 2019: Gross Value Accumulated Net Book Weighted- (in thousands) (years) Customer relationships $ 8,190 $ (1,227) $ 6,963 7.1 Developed technology 11,020 (1,848) 9,172 5.7 Trade names 448 (114) 334 4.0 Total $ 19,658 $ (3,189) $ 16,469 Amortization expense for intangible assets for the three and six months ended June 30, 2020 and 2019 is as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 (in thousands) Customer relationships $ 251 $ 251 $ 502 $ 418 Developed technology 419 353 839 730 Trade names 22 25 47 45 Total $ 692 $ 629 $ 1,388 $ 1,193 The expected future amortization expense related to intangible assets as of June 30, 2020 was as follows: Amount (in thousands) Remainder of 2020 $ 1,381 2021 2,762 2022 2,750 2023 2,494 2024 2,324 Thereafter 3,370 Total $ 15,081 Goodwill Goodwill was $35.8 million as of June 30, 2020 and December 31, 2019. Through June 30, 2020, there has not been any impairment of goodwill. Other Noncurrent Assets Other noncurrent assets consisted of the following: June 30, December 31, 2020 2019 (in thousands) Escrow deposit, noncurrent $ — $ 3,150 Other 569 310 Total $ 569 $ 3,460 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: June 30, December 31, 2020 2019 (in thousands) Accrued bonus $ 6,654 $ 8,652 Vendor accruals 4,888 3,984 Contingent consideration, current 2,445 3,004 Accrued commissions 3,827 2,611 Accrued payroll and employee benefits 2,837 2,291 Accrued sales and use taxes 1,043 932 Accrued rebates 1,642 1,152 Employee contribution to ESPP 721 1,805 Accrued Interest 361 — Operating lease liabilities, current 3,130 — Other accrued expenses 8,136 3,370 Total $ 35,684 $ 27,801

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following table sets forth the fair value of our financial assets and liabilities by level within the fair value hierarchy: June 30, 2020 Level 1 Level 2 Level 3 Fair Value (in thousands) Assets Short-term investment: Certificate of deposit 150,000 — — 150,000 Total assets at fair value $ 150,000 $ — $ — $ 150,000 Liabilities Other current liabilities—contingent consideration $ — $ — $ 2,445 $ 2,445 Total liabilities at fair value $ — $ — $ 2,445 $ 2,445 December 31, 2019 Level 1 Level 2 Level 3 Fair Value (in thousands) Assets Cash equivalents: Money market funds $ 130,640 $ — $ — $ 130,640 Short-term investment: Certificate of deposit $ 150,000 $ — $ — $ 150,000 Total assets at fair value $ 280,640 $ — $ — $ 280,640 Liabilities Other current liabilities—contingent consideration $ — $ — $ 3,004 $ 3,004 Other noncurrent liabilities—contingent consideration — — 2,411 2,411 Total liabilities at fair value $ — $ — $ 5,415 $ 5,415 Cash, Cash Equivalents and Short-Term Investments Our valuation techniques used to measure the fair value of Level 1 assets are derived from quoted prices in active markets for identical assets or liabilities. Cash, cash equivalents and short-term investments were as follows (in thousands): June 30, 2020 Adjusted Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Cash $ 685,953 $ — $ — $ 685,953 Money market funds — — $ — — Total cash, and cash equivalents 685,953 — — 685,953 Certificate of deposit 150,000 — — 150,000 Total short-term investments 150,000 — — 150,000 Total cash, cash equivalents and short-term investments $ 835,953 $ — $ — $ 835,953 December 31, 2019 Adjusted Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Cash $ 111,098 $ — $ — $ 111,098 Money market funds 130,640 — — 130,640 Total cash, and cash equivalents 241,738 — — 241,738 Certificate of deposit 150,000 — 150,000 Total short-term investments 150,000 — — 150,000 Total cash, cash equivalents and short-term investments $ 391,738 $ — $ — $ 391,738 Contingent Consideration Liability In connection with the Retrofit Acquisition in April 2018, we recorded a contingent consideration liability, which is payable subject to the achievement of certain targets for 2018, 2019, and 2020. In connection with the myStrength Acquisition in February 2019, we recorded a contingent liability, which was payable subject to the achievement of certain targets for 2019 and was paid in February 2020. The fair values of these contingent consideration liabilities were estimated with a Monte Carlo simulation model using Level 3 inputs to assess the probability of us achieving the targets, and any subsequent changes in fair value are recorded in the condensed consolidated statements of operations until settlement. As of June 30, 2020, the significant inputs for the fair value of the remaining contingent liability included projected qualifying members for fiscal year 2020, weighted-average revenue volatility of 5.10%, weighted-average revenue discount rate of 0.6%, and weighted-average discount rate of 0.17%. See Note 5 for further discussion. As of June 30, 2020 and December 31, 2019, total contingent consideration liabilities were $2.4 million and $5.4 million, respectively. The following table sets forth the changes in our contingent consideration liability for the periods presented: Six Months Ended June 30, 2020 2019 (in thousands) Beginning balance $ 5,415 $ 5,004 Contingent consideration recorded upon acquisition (Note 5) — 3,300 Change in fair value of contingent consideration (Note 5) 86 955 Payment related to Retrofit contingent consideration (Note 5) (472) (1,316) Payment related to myStrength contingent consideration (Note 5) (2,584) — Ending balance $ 2,445 7,943

Operating Lease Liabilities

Operating Lease Liabilities	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Operating Lease Liabilities	Operating Lease Liabilities We lease office facilities under operating lease arrangements that have remaining lease terms ranging from 3 to 7 years. Our leases do not contain any material residual value guarantees or restrictive covenants. During the three and six months ended June 30, 2020, operating lease costs for non-cancelable operating lease costs were $0.9 million and $1.9 million, respectively. Variable lease costs were $0.1 million and $0.3 million for the three and six months ended June 30, 2020, respectively. Sublease income for the three and six months ended June 30, 2020 were not material. Under ASC 840, the previous lease standard, total rent expense under operating leases during the three and six months ended June 30, 2019 was $0.6 million and $1.2 million, respectively. A summary of supplemental lease information is as follows: June 30, 2020 (in thousands) Weighted average remaining lease term (years) 4.5 Weighted average discount rate 3.8 % Maturities of operating lease liabilities as of June 30, 2020 are as follows: June 30, 2020 (in thousands) Years ending December 31, 2020 (remaining 6 months) $ 2,490 2021 5,094 2022 5,242 2023 5,213 2024 1,799 2025 and thereafter 3,071 Total lease payments 22,909 Less: imputed interest (1,963) Less: tenant allowance (2,058) Total operating lease liabilities $ 18,888 Reported as: Operating lease liabilities, current (1) $ 3,130 Operating lease liabilities, noncurrent 15,758 Total operating lease liabilities $ 18,888 (1) Included as part of "Accrued expenses and other current liabilities" on the condensed consolidated balance sheets. Future minimum lease payments, net of future sublease income of $0.2 million, under operating leases as of December 31, 2019 under ASC 840, the prior lease standard, were as follows: Net Minimum (in thousands) 2020 $ 3,908 2021 5,055 2022 5,233 2023 5,141 2024 1,756 Thereafter 3,068 Total future minimum payments $ 24,161

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Matters From time to time, we become involved in claims and other legal matters arising in the ordinary course of business. We investigate these claims as they arise. Although claims are inherently unpredictable, we are currently not aware of any matters that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial position or cash flows. We record liabilities for legal and other contingencies when losses are probable and estimable. Although the results of litigation and claims are inherently unpredictable, we have not recorded an accrual for such contingencies as we believe that there was not at least a reasonable possibility that we had incurred a material loss with respect to such loss contingencies as of June 30, 2020, and December 31, 2019. Indemnification We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, including, but not limited to, clients, business partners, landlords, contractors and parties performing our research and development. Pursuant to these arrangements, we agree to indemnify, hold harmless, and reimburse the indemnified party for certain losses suffered or incurred by the indemnified party as a result of our activities. The terms of these indemnification agreements are generally perpetual. The maximum potential amount of future payments we could be required to make under these agreements is not determinable. We have never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, we believe the fair value of these agreements is not material. We maintain commercial general liability insurance and product liability insurance to offset certain of our potential liabilities under these indemnification provisions. In addition, we indemnify our officers, directors and certain key employees while they are serving in good faith in their respective capacities. To date, there have been no claims under these indemnification provisions.

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Stockholders’ Equity	Stockholders’ Equity Redeemable Convertible Preferred Stock In conjunction with our IPO in July 2019, all shares of redeemable convertible preferred stock then outstanding, totaling 58,615,488 shares, were automatically converted into an equivalent number of shares of common stock on a one-to-one basis and their carrying value, totaling $237.0 million, inclusive of accretion of redeemable convertible preferred stock, was reclassified into stockholders’ equity on our condensed consolidated balance sheets. No shares of redeemable convertible preferred stock were issued or outstanding as of June 30, 2020 or December 31, 2019. Accretion to the redemption price of our redeemable convertible preferred stock was less than $0.1 million for the three and six months ended June 30, 2019, and zero for the three and six months ended June 30, 2020. Accretion is recognized as a reduction of additional paid-in capital with a corresponding increase to the carrying value of our redeemable convertible preferred stock. Upon completion of the IPO, the accretion rights of our redeemable convertible preferred stock were terminated. Undesignated Preferred Stock In connection with the IPO, we filed an Amended and Restated Certificate of Incorporation which authorizes the issuance of 100,000,000 shares of undesignated preferred stock, par value of $0.001 per share, with rights and preferences, including voting rights, designated from time to time by our board of directors. Common Stock In December 2019, we completed a secondary offering in which certain stockholders sold 2,777,327 shares of common stock at an offering price of $27.00 per share. The selling stockholders received all of the net proceeds from the sale of shares in this offering. We did not sell any shares or receive any proceeds in this secondary offering. In July 2019, upon completion of our IPO, we sold 14,590,050 shares of our common stock at an offering price of $28.00 per share, including 1,903,050 shares of common stock pursuant to the exercise in full of the underwriters' option to purchase additional shares. We raised net proceeds of $377.5 million, after deducting underwriting discounts and commissions of $28.6 million and offering costs of approximately $2.4 million. In connection with the IPO, we filed an Amended and Restated Certificate of Incorporation which authorizes the issuance of 900,000,000 shares of common stock with a par value of $0.001 per share. As of June 30, 2020 and December 31, 2019, we reserved shares of common stock, on an as-if-converted basis, for future issuance as follows: June 30, December 31, 2020 2019 (in thousands) Outstanding warrants to purchase common stock 695 695 Outstanding options to purchase common stock 11,011 14,020 Outstanding restricted stock units 4,785 5,208 Restricted stock awards subject to repurchase 614 736 Estimated shares for future ESPP purchase 1,752 890 Convertible senior notes 7,278 — Available for future issuance under 2019 Plan 11,485 8,160 Total 37,620 29,709 Common stock warrants outstanding as of June 30, 2020 and December 31, 2019 were as follows: Holder Issue Date Outstanding Exercise Exercisable Expiration (in thousands, except per share data) Partner 3/1/2015 695 $2.28 695 2/28/2025 695 695

Common Stock Warrants

Common Stock Warrants	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Common Stock Warrants	Stockholders’ Equity Redeemable Convertible Preferred Stock In conjunction with our IPO in July 2019, all shares of redeemable convertible preferred stock then outstanding, totaling 58,615,488 shares, were automatically converted into an equivalent number of shares of common stock on a one-to-one basis and their carrying value, totaling $237.0 million, inclusive of accretion of redeemable convertible preferred stock, was reclassified into stockholders’ equity on our condensed consolidated balance sheets. No shares of redeemable convertible preferred stock were issued or outstanding as of June 30, 2020 or December 31, 2019. Accretion to the redemption price of our redeemable convertible preferred stock was less than $0.1 million for the three and six months ended June 30, 2019, and zero for the three and six months ended June 30, 2020. Accretion is recognized as a reduction of additional paid-in capital with a corresponding increase to the carrying value of our redeemable convertible preferred stock. Upon completion of the IPO, the accretion rights of our redeemable convertible preferred stock were terminated. Undesignated Preferred Stock In connection with the IPO, we filed an Amended and Restated Certificate of Incorporation which authorizes the issuance of 100,000,000 shares of undesignated preferred stock, par value of $0.001 per share, with rights and preferences, including voting rights, designated from time to time by our board of directors. Common Stock In December 2019, we completed a secondary offering in which certain stockholders sold 2,777,327 shares of common stock at an offering price of $27.00 per share. The selling stockholders received all of the net proceeds from the sale of shares in this offering. We did not sell any shares or receive any proceeds in this secondary offering. In July 2019, upon completion of our IPO, we sold 14,590,050 shares of our common stock at an offering price of $28.00 per share, including 1,903,050 shares of common stock pursuant to the exercise in full of the underwriters' option to purchase additional shares. We raised net proceeds of $377.5 million, after deducting underwriting discounts and commissions of $28.6 million and offering costs of approximately $2.4 million. In connection with the IPO, we filed an Amended and Restated Certificate of Incorporation which authorizes the issuance of 900,000,000 shares of common stock with a par value of $0.001 per share. As of June 30, 2020 and December 31, 2019, we reserved shares of common stock, on an as-if-converted basis, for future issuance as follows: June 30, December 31, 2020 2019 (in thousands) Outstanding warrants to purchase common stock 695 695 Outstanding options to purchase common stock 11,011 14,020 Outstanding restricted stock units 4,785 5,208 Restricted stock awards subject to repurchase 614 736 Estimated shares for future ESPP purchase 1,752 890 Convertible senior notes 7,278 — Available for future issuance under 2019 Plan 11,485 8,160 Total 37,620 29,709 Common stock warrants outstanding as of June 30, 2020 and December 31, 2019 were as follows: Holder Issue Date Outstanding Exercise Exercisable Expiration (in thousands, except per share data) Partner 3/1/2015 695 $2.28 695 2/28/2025 695 695

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation We have the following stock-based compensation plans: the EosHealth, Inc. 2008 Stock Incentive Plan (the “2008 Plan”), the Livongo Health, Inc. 2014 Stock Incentive Plan (the “2014 Plan”), and the 2019 Equity Incentive Plan (the "2019 Plan", and, together with the 2014 Plan and the 2008 Plan, the "Plans"). Our 2019 Plan became effective as of the business day immediately prior to the effective date of our IPO. A total of 8,004,000 shares of our common stock was initially reserved for issuance pursuant to our 2019 Plan. In addition, the shares reserved for issuance under our 2019 Plan include (i) shares that were reserved but unissued under our 2014 Plan as of immediately prior to its termination, plus (ii) shares subject to awards under our 2014 Plan, and our 2008 Plan that, on or after the termination of the 2014 Plan, expire or terminate and shares previously issued pursuant to our 2014 Plan or 2008 Plan, as applicable, that, on or after the termination of the 2014 Plan, are forfeited or repurchased by us (provided that the maximum number of shares that may be added to our 2019 Plan from the 2014 Plan and 2008 Plan is 21,770,029 shares). The number of shares of our common stock available for issuance under our 2019 Plan will also include an annual increase on the first day of each fiscal year beginning on January 1, 2020, equal to the least of: (i) 7,120,000 shares; (ii) 4% of the outstanding shares of our common stock as of the last day of our immediately preceding fiscal year; or (iii) such other amount as our board of directors may determine as of no later than the last day of our immediately preceding fiscal year. Stock Options Stock option activity under the Plans is as follows: Options Outstanding Shares Shares Weighted- Weighted- Aggregate (in thousands, except per share data and years) Balance as of December 31, 2019 8,160 14,020 $ 1.85 6.7 $ 325,474 Shares authorized 3,812 — Exercised — (2,837) $ 1.36 Forfeited/cancelled 172 (172) $ 2.05 Restricted stock units and PSUs granted (1,430) — Restricted stock units and PSUs forfeited 278 — Restricted stock units and PSUs withheld for income taxes 493 — Balance as of June 30, 2020 11,485 11,011 $ 1.97 6.4 $ 806,215 Vested and exercisable as of June 30, 2020 8,221 $ 1.64 6.1 $ 604,619 The aggregate intrinsic value of stock option awards exercised was $74.7 million and $23.9 million for the three months ended June 30, 2020 and 2019, respectively, and $105.9 million and $28.1 million for the six months ended June 30, 2020 and 2019, respectively. Aggregate intrinsic value represents the difference between the exercise price and the fair value of the shares underlying common stock on the date of exercise. No options were granted during the three and six months ended June 30, 2020 and 2019. As of June 30, 2020, total unrecognized compensation expense related to unvested stock options, Performance RSUs and restricted stock units granted was $82.8 million, which is expected to be recognized over a weighted-average period of 3.5 years. Options and Restricted Stock Units with Service- and Market-Based Vesting Conditions In March 2019, we canceled stock options with a combination of service- and market-based vesting conditions covering a total of 196,460 shares that were granted in 2018. In January 2019, we granted restricted stock units covering a total of 161,250 shares with a combination of service- and market-based vesting conditions to an executive. We recognized stock-based compensation expense of $0.2 million and $0.2 million for the three months ended June 30, 2020 and 2019, respectively, and $0.4 million and $0.6 million for the six months ended June 30, 2020 and 2019, respectively, in connection with these service- and market-based grants. Additionally, we recognized stock-based compensation expense of $0.2 million related to the canceled market-based options for the six months ended June 30, 2019. The unrecognized stock-based compensation expense for market-based awards as of June 30, 2020 was $1.2 million, which is expected to be recognized over a weighted-average period of 2.2 years. Restricted Stock Awards Shares Weighted- (in thousands, except per share data) Unvested balance, December 31, 2019 736 $ 9.76 Vested (122) $ 9.76 Unvested balance, June 30, 2020 614 $ 9.76 In March 2019, we issued a restricted stock award covering 982,301 shares of our common stock to an executive with a grant date fair value of $9.6 million. We recognized restricted stock awards related stock-based compensation expense of $0.5 million and $2.9 million for the three months ended June 30, 2020 and 2019, respectively, and $1.0 million and $3.1 million for the six months ended June 30, 2020 and 2019, respectively. As of June 30, 2020, the unrecognized stock-based compensation expense related to these restricted stock awards was $4.5 million, which is expected to be recognized over a weighted-average period of 2.2 years. Restricted Stock Units and Performance Stock Units Restricted Weighted- (in thousands, except per Balance as of December 31, 2019 4,708 $ 11.31 Granted 1,429 $ 42.48 Released (1,074) $ 9.96 Forfeited (278) $ 12.03 Balance as of June 30, 2020 4,785 $ 13.52 Prior to our IPO, we granted restricted stock units that contain both service- and performance-based vesting conditions to our executives, employees and consultants (“Performance RSUs”). The service-based vesting condition is generally satisfied (i) over four years with 25% vesting on the one-year anniversary of the award and the remainder vesting monthly over the next 36 months, or (ii) over four years with 1/48 vesting on the one-month anniversary of the award, and remainder vesting monthly over the next 47 months, subject to the grantee’s continued service with us through the vesting dates. The performance-based vesting condition is satisfied upon the earlier of (i) a change in control where the consideration paid to our equity security holders is cash, publicly traded stock, or a combination of both, or (ii) six months and one day following our IPO. The satisfaction of the performance-based vesting condition became probable upon the completion of our IPO in July 2019, at which point we recorded cumulative stock-based compensation expense using the accelerated attribution method. During the three months ended March 31, 2020, the vesting terms for Performance RSUs were modified from monthly to quarterly basis. The modification had no material impact on our condensed consolidated financial statements. Subsequent to our IPO in July 2019, we grant restricted stock units to our executives, employees and consultants that only contain service-based vesting conditions ("RSUs"). The service-based vesting condition is generally satisfied over four years on a quarterly basis, with each 1/16 vesting on prefixed quarterly vesting anchor dates, subject to the grantee's continued service with us through the vesting dates. In January 2019, we granted restricted stock units covering 982,301 shares to an executive that contain only service-based vesting conditions over a four Additionally, included in the shares granted during the six months ended June 30, 2020, we issued performance-based restricted stock units covering 23,196 shares which consist of both service- and performance-based conditions. The service-based vesting condition is satisfied over one year on a quarterly basis from the date the applicable sales milestones are met. The performance-based vesting condition is satisfied upon the achievement of certain sales milestones. In April 2019, we issued other performance-based restricted stock units covering 100,000 shares which consist of both service- and performance-based vesting conditions including both the achievement of certain sales milestones and our IPO. The service-based vesting condition is satisfied over four years from the date the sales milestones were met. The performance-based vesting condition was satisfied upon both the achievement of certain sales milestones and our IPO. Stock-based compensation expense related to these performance-based restricted stock units that are expected to vest was $0.1 million and $0.2 million during the three and six months ended June 30, 2020, respectively. 2019 Employee Stock Purchase Plan In July 2019, our board of directors adopted, and our stockholders approved, our Employee Stock Purchase Plan ("ESPP"). Our ESPP became effective as of the business day immediately prior to the effective date of our IPO. A total of 890,000 shares of our common stock was initially available for sale under our ESPP. In addition, the number of shares available for sale under our ESPP will include an annual increase on the first day of each fiscal year beginning on January 1, 2020, equal to the least of: (i) 2,670,000 shares, (ii) 1% of the outstanding shares of our common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as our board of directors may determine as of no later than the last day of our immediately preceding fiscal year. Each offering period will be approximately six months in duration commencing on the first trading day on or after May 15 and November 15 of each year and terminating on the first trading day on or after November 15 and May 15 approximately six months later, provided however that the first offering period commenced on the first trading day after our IPO date and will end on May 15, 2020. All regular employees, including executive officers, employed by us or by any of our designated affiliates, except for those holding 5% or more of the total combined voting power or value of our common stock, may participate in the ESPP and may contribute, normally through payroll deductions, up to 15% of their earnings (as defined in the ESPP) for the purchase of our common stock under the ESPP. Unless otherwise determined by our board of directors, the purchase price of the shares will be 85% of the lower of the fair market value of our common stock on the first trading day of each offering period or on the purchase date, subject to a limit of the lesser of (i) 500 shares of our common stock, or (ii) $12,500 divided by the fair market value of our common stock as of the first day of the offering period, with any resulting fractional share rounded down to the nearest whole share. As of June 30, 2020, 90,613 shares of common stock have been purchased under our ESPP. During the three and six months ended June 30, 2020, we recognized $0.4 million and $0.9 million, respectively, in stock-based compensation expense related to our ESPP in our condensed consolidated statements of operations. As of June 30, 2020, the unrecognized stock-based compensation expense related to our ESPP is $0.7 million, which is expected to be recognized over a weighted average period of 0.1 year. Award Modifications In March 2020, we accelerated vesting of 11,412 RSUs for terminated employees, resulting in an incremental stock-based compensation expense of $0.1 million recognized in the consolidated statements of operations for the six months ended June 30, 2020. Stock-Based Compensation Expense Stock-based compensation expense in the condensed consolidated statements of operations is summarized as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 (in thousands) Cost of revenue $ 118 $ 6 $ 210 12 Research and development expenses 1,593 491 3,809 852 Sales and marketing expenses 2,364 41 4,416 260 General and administrative expenses 5,800 3,915 9,503 8,839 Total stock-based compensation expense $ 9,875 $ 4,453 $ 17,938 $ 9,963 Stock-based compensation costs related to capitalized internal-use software during the three and six months ended June 30, 2020 was $0.2 million and $0.3 million, respectively and less than $0.1 million for the three months and six months ended June 30, 2019.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes We recorded an insignificant income tax expense for the six months ended June 30, 2020, primarily due to state taxes and income taxes on foreign income. The income tax benefit of $1.4 million for the six months ended June 30, 2019 was due to the release of a valuation allowance arising from a deferred tax liability in connection with the myStrength acquisition. The deferred tax liability provided an additional source of taxable income to support the realizability of pre-existing deferred tax assets. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was enacted and signed into law. The CARES Act includes a number of income tax changes, including, but not limited to, (i) permitting net operating loss carrybacks to offset 100% of taxable income for taxable years beginning before 2021, (ii) accelerating AMT tax refunds, (iii) temporarily increasing the allowable business interest deduction from 30% to 50% of adjusted taxable income, and (iv) providing a technical correction for depreciation as relates to qualified improvement property. We have preliminarily evaluated the impact of the CARES Act and do not expect the CARES Act will result in material impact.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	Net Loss Per Share Attributable to Common Stockholders The following table sets forth the computation of basic and diluted net loss per share attributable to our common stockholders: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 (in thousands, except per share data) Net loss $ (1,554) $ (12,977) $ (7,127) $ (27,348) Accretion of redeemable convertible preferred stock — (42) — (83) Net loss attributable to common stockholders $ (1,554) $ (13,019) $ (7,127) $ (27,431) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 97,896 18,916 96,719 18,564 Net loss per share attributable to common stockholders, basic and diluted $ (0.02) $ (0.69) $ (0.07) $ (1.48) As we have reported net loss for each of the periods presented, all potentially dilutive securities are antidilutive. The following potential outstanding shares of common stock were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 (in thousands) Redeemable convertible preferred stock — 58,615 — 58,615 Stock options 11,011 15,352 11,011 15,352 Restricted stock awards subject to repurchase 614 736 614 736 Common stock warrants 695 785 695 785 Restricted stock units 4,785 1,207 4,785 1,207 Convertible senior notes 7,278 — 7,278 — ESPP obligations 14 — 14 — Total anti-dilutive shares 24,397 76,695 24,397 76,695 Based on the initial conversion price of $75.57, the entire outstanding principal amount of the convertible senior notes as of June 30, 2020 would have been convertible into 7,278 shares of our common stock. These shares were not considered in the calculation of diluted net loss per share attributable to common stockholders as the effect would have been anti-dilutive for the three and six months ended June 30, 2020 due to our net losses for those periods.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Segment Information	Segment InformationWe operate as one operating segment as we only report financial information on an aggregate and consolidated basis to the Chief Executive Officer, our chief operating decision maker, who regularly reviews financial operating results on a consolidated basis for purposes of allocating resources and evaluating financial performance. There are no segment managers who are held accountable for operations, operating results, and plans for components or types of products or services below the consolidated unit level. As of June 30, 2020 and December 31, 2019, substantially all of our long-lived assets were located in the United States and all revenue was earned in the United States for the three and six months ended June 30, 2020 and 2019.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions In January 2020, we entered into an agreement with a service provider for which our Founder and Executive Chairman is a board member. Amounts paid to this service provider totaled $0.1 million during the six months ended June 30, 2020. During the three and six months ended June 30, 2020 and 2019, we paid immaterial shared service fees related to financial, legal, and administrative support to a stockholder pursuant to a shared services agreement.

Employee Benefits

Employee Benefits	6 Months Ended
	Jun. 30, 2020
Retirement Benefits [Abstract]
Employee Benefits	Employee BenefitsWe sponsor a 401(k) plan for employees, which provides for us to make discretionary matching or discretionary annual contributions to the plan. We recognized expense of $0.2 million and $0.9 million for the three and six months ended June 30, 2020, respectively, and $0.3 million and $0.6 million for the three and six months ended June 30, 2019, respectively, related to our 401(k) plan.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event On August 5, 2020, we entered into an Agreement and Plan of Merger (the “Merger Agreement”), with Teladoc Health, Inc, a Delaware corporation (“Teladoc”), and Tempranillo Merger Sub, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Teladoc (“Merger Sub”). The Merger Agreement provides that, subject to the satisfaction of customary closing conditions, Merger Sub will be merged with and into Livongo (the “Merger”), with Livongo continuing as the surviving corporation and a direct, wholly-owned subsidiary of Teladoc. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each share of our common stock, par value $0.001 per share, issued and outstanding immediately prior to the effective time of the Merger (other than shares held by any shareholder who properly demands and perfects his, her or its appraisal rights with respect to such shares and treasury shares held by Livongo) will be converted into the right to receive (i) 0.5920 of a share of common stock, par value $0.001 per share, of Teladoc and (ii) $4.24 in cash, without any interest thereon. In addition, prior to the effective time of the Merger, we will declare a special cash dividend equal to $7.09 per share of common stock to shareholders of Livongo as of a record date immediately prior to the effective time of the Merger. The Merger, which is currently expected to close in the fourth quarter of 2020, is subject to the satisfaction or waiver of certain customary closing conditions, including, among others, (i) adoption of the Merger Agreement by the affirmative vote of holders of a majority of outstanding shares of our common stock, (ii) approval of an amendment to Teladoc’s certificate of incorporation by the affirmative vote of the holders of a majority of outstanding shares of Teladoc’s common stock and approval of the issuance of shares pursuant to the Merger Agreement by the affirmative vote of holders of a majority of all votes cast by holders of outstanding shares of Teladoc’s common stock, and (iii) the termination or expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976. The Merger Agreement contains certain termination rights for both us and Teladoc. If the Merger Agreement is terminated under certain specified circumstances, we will be required to pay Teladoc a termination fee of $562,810,000 (including in connection with our entry into an agreement with respect to a superior proposal, as defined in the Merger Agreement, if certain conditions are met).

Summary of Significant Accoun_2

Summary of Significant Accounting Policies - (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of Livongo Health, Inc. and our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated. The condensed consolidated balance sheet as of December 31, 2019 included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by U.S. GAAP. The accompanying interim condensed consolidated balance sheets as of June 30, 2020, the interim condensed consolidated statements of operations and the interim condensed consolidated statements of redeemable convertible preferred stock and stockholders’ deficit for the three and six months ended June 30, 2020 and 2019, and the interim condensed consolidated statements of cash flows for the six months ended June 30, 2020 and 2019 are unaudited. These interim condensed consolidated financial statements have been prepared on a basis consistent with the annual consolidated financial statements and, in the opinion of management, include all adjustments necessary to fairly state our financial position as of June 30, 2020, the results of our operations for the three and six months ended June 30, 2020 and 2019 and result of our cash flows for the six months ended June 30, 2020 and 2019. The financial data and other financial information disclosure in the notes to these interim condensed consolidated financial statements related to the three and six months periods are also unaudited. The results for the three and six months ended June 30, 2020 are not necessarily indicative of the operating results expected for the year ending December 31, 2020 or any future period. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related footnotes included in our latest annual report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 24, 2020. We have revised our condensed consolidated statements of operations and cash flows for the three and six months ended June 30, 2019 to reflect the adoption of Accounting Standards Update ("ASU") No. 2014-09 We made other adjustments to our financial results for the first quarter through the third quarter of 2019 to correct errors that consist of (i) a $1.9 million total adjustment for the capitalization and amortization of device costs for Livongo for Hypertension and Livongo for Prediabetes and Weight Management, (ii) a $1.2 million total reduction of sales and marketing expenses for the capitalization and amortization of certain sales commissions, and (iii) a $0.4 million increase in sales and marketing expenses. We evaluated the materiality of these revisions, quantitatively and qualitatively, and determined that these revisions were not material to any of our previously issued condensed consolidated financial statements. In addition, in connection with the preparation of our 2019 Annual Report on Form 10-K, we identified an immaterial error in the condensed consolidated statements of cash flows for the second and third quarterly periods of 2019 included in our 2019 Quarterly Reports on Form 10-Q relating to the release of an escrow deposit for a prior acquisition that was incorrectly classified as a cash outflow within investing activities. We have corrected the error in the accompanying six months ended June 30, 2019 condensed consolidated statement of cash flows by decreasing cash flows used in investing activities by $1.3 million and increasing cash flows used in financing activities by $1.3 million.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the financial statements, as well as the reported amounts of revenue and expenses during the periods presented. Such estimates, judgments, and assumptions include: revenue recognition, allowance for doubtful accounts, the period of benefit for deferred commissions, the period of benefit for deferred device costs, estimated costs for capitalized internal-use software, assessment of the useful life and recoverability of long-lived assets, fair values of stock-based awards, contingent consideration in business combinations, the incremental borrowing rate ("IBR") applied in lease accounting, effective interest rate of the liability component of our Notes, income taxes, and fair value of Notes. Actual results could be different from these estimates. While the COVID-19 pandemic has not had a material adverse impact on our results of operations to date, our estimates for revenue recognition and allowance for doubtful accounts, as well as our other estimates, judgments, and assumptions, may be materially and adversely different from our actual results as a result of the COVID-19 pandemic. To the extent there are material differences between these estimates, judgments, or assumptions and actual results, our financial statements will be affected.
Emerging Growth Company Status	Emerging Growth Company StatusWe are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period and, as a result, we may not adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies until required by private company accounting standards.
Concentration of Risk	Concentration of Risk Financial instruments that potentially subject us to credit risk consist principally of cash, cash equivalents, certificates of deposit, accounts receivable and the Capped Call Transactions (Note 3). We maintain our cash primarily with domestic financial institutions of high credit quality, which may exceed federal deposit insurance corporation limits. We invest our cash equivalents in highly rated money market funds and short-term investments in certificates of deposit. We have not experienced any losses in such accounts. We believe we are not exposed to any significant credit risk on cash, cash equivalents, investments and restricted cash and perform periodic evaluations of the credit standing of such institutions. Our sales are predominately to self-insured employers, healthcare providers, and insurance carriers located throughout North America. Accounts receivable are recorded at the invoiced amount, and are stated at realizable value, net of an allowance for doubtful accounts. We perform ongoing assessments of our clients to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with clients. We have not experienced material credit losses from our accounts receivable. Significant clients and partners are those which represent 10% or more of our net accounts receivable balance or revenue during the period at each respective consolidated balance sheet date.
Recent Accounting Pronouncements Adopted and New Account Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Adopted in Fiscal 2020 Leases: In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-02 Leases (Topic 842) and subsequent amendments to the initial guidance (collectively, "ASC 842"), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. This ASU is effective for us for the interim periods and year ending December 31, 2020. Early adoption is permitted. We adopted ASC 842 on January 1, 2020 using the modified retrospective approach by electing to use the optional transition method which allows us to continue to apply the previous guidance, including disclosure requirements, in the comparative periods presented. We elected to use certain practical expedients permitted under the transition guidance within the new guidance, which allows us to carry forward the historical accounting relating to lease identification and classification for existing leases upon adoption. We also elected not to use the hindsight practical expedient in determining the lease term and impairment of the operating lease right-of-use ("ROU") assets and elected not to record operating leases with an initial term of 12 months or less on our condensed consolidated balance sheets. We elected not to separate lease and non-lease components for all classes of underlying assets. Adoption of the new lease standard resulted in the recording of ROU assets and operating lease liabilities of approximately $18.1 million and $18.6 million, respectively, as of January 1, 2020. The difference between the ROU assets and operating lease liabilities primarily relates to deferred rent of $0.5 million recorded in accordance with the previous lease guidance. The adoption had no impact on total cash flows from operations other than a change within operating cash flows. We determine if an arrangement is or contains a lease at inception. Our lease agreements do not contain any material options to extend or terminate leases, any material residual value guarantees, any material restrictions or covenants, or any material variable lease payments. Any variable lease payments consist of common area maintenance, taxes and other costs and are expensed as incurred. We have performed an evaluation of our other contracts with customers and suppliers in accordance with ASC 842 and have determined that, none of our other contracts contain a lease. ROU assets represent our right to use an underlying asset for the lease term, while operating lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. In determining the present value of lease payments, we use our IBR based on the information available at the lease commencement date, including the lease term, for operating leases. The incremental borrowing rate is a hypothetical rate based on our understanding of what our credit rating would be for a secured borrowing in the country where the lease was executed. Upon adoption, the ROU asset was valued at the amount of the operating lease liabilities adjusted for lease incentives, prepaid rent, and deferred rent as of January 1, 2020. The adoption of the new standard resulted in changes to our accounting policies for leases and in additional disclosures. See Note 8. Stock-Based Compensation: In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting . The standard simplifies the accounting for share-based payments granted to nonemployees for goods and services and aligns most of the guidance on such payments to the nonemployees with the requirements for share-based payments granted to employees. ASU No. 2018-07 is effective for us for the interim periods and the year beginning January 1, 2020. Early adoption is permitted. We adopted this new standard using a prospective method on January 1, 2020. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. Disclosure of Fair Value Measurement: In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of the FASB's disclosure framework project. The new standard is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including interim reporting periods within those fiscal years. ASU 2018-13 is effective for us for the interim periods and the year beginning January 1, 2020. We adopted the new standard using a prospective method effective on January 1, 2020. The adoption of this ASU resulted in additional disclosures in Note 7 of our condensed consolidated financial statements. Cloud Computing Arrangements Implementation Costs : In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use-software. This ASU is effective for us for the year ending December 31, 2021, and interim periods within the year ending December 31, 2022. Early adoption is permitted. We early adopted this new standard on a prospective method effective on April 1, 2020, which did not have a material impact on the Company's condensed consolidated financial statements. New Accounting Pronouncements Not Yet Adopted Credit Losses: In June 2018, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . The standard requires a financial asset measured at amortized cost basis to be presented at the net amount expected to be collected, with further clarifications made more recently. For trade receivables, loans, and other financial assets, we will be required to use a forward-looking expected loss model rather than the incurred loss model for recognizing credit losses which reflects losses that are probable. Credit losses relating to available-for-sale debt securities are required to be recorded through an allowance for credit losses rather than a reduction in the amortized cost basis of the securities. This new standard is effective for us for the interim periods within and the year ending December 31, 2020. Early adoption is permitted. We are currently evaluating the impact of this ASU on our consolidated financial statements. Income Taxes : In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which simplifies that accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amending existing guidance to improve consistent application. This new standard is effective for our interim periods within and year ending December 31, 2021. Early adoption is permitted. Most amendments within this standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - (Tables)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Schedules of Concentration Risk	For each significant client that represented 10% or more of our accounts receivable balance or revenue during the three and six months ended June 30, 2020, revenue as a percentage of total revenue and accounts receivable as a percentage of net accounts receivable were as follows: Revenue Accounts Receivable Three Months Ended June 30, Six Months Ended June 30, June 30, December 31, 2020 2019 2020 2019 2020 2019 (unaudited) Client A 25 % — % 21 — % 12 % — % Our significant client was contracted through a partner, which is not shown below as the only revenue and our accounts receivable balance for such significant partner is from our significant client. For each significant partner that represented 10% or more of our accounts receivable balance or revenue during the periods presented, revenue as a percentage of total revenue and accounts receivable as a percentage of net accounts receivable were as follows: Revenue Accounts Receivable Three Months Ended June 30, Six Months Ended June 30, June 30, December 31, 2020 2019 2020 2019 2020 2019 (unaudited) Partner A 17 % 27 % 20 % 26 % 17 % 23 % Partner B 15 % 24 % 16 24 % 21 % 25 %

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Convertible Debt	The carrying value of the Notes consisted of the following (in thousands): As of June 30, 2020 Liability component: Principal $ 550,000 Less: unamortized discount (142,324) Less: unamortized issuance costs (11,230) Net carrying amount $ 396,446 Equity component: Notes $ 144,106 Less: issuance costs (4,036) Carrying amount of the equity component (1) $ 140,070 (1) Included in the consolidated balance sheets within Additional paid-in capital. Total interest expense on the Notes, reflecting the effective interest rate of 7.72%, was as follows for the three and six months ended June 30, 2020 (in thousands): Three and six months ended June 30, 2020 Contractual interest expense $ 361 Amortization of debt discount 1,781 Amortization of issuance costs 141 Total $ 2,283
Schedule of Maturities of Long-term Debt	The following table summarizes the payments due by period for the Notes. Payments Due by Period Less than 1 Year 1-3 Years 3-5 Years More than 5 Years Total (in thousands) Payment of principal and interest of convertible senior notes $ 4,772 $ 9,625 $ 559,625 $ — $ 574,022

Revenue, Deferred Revenue and D

Revenue, Deferred Revenue and Deferred Costs and Other (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Contract with Customer, Asset and Liability	Deferred revenue activity is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2020 2019 2020 2019 Balance at beginning of period $ 6,099 $ 3,527 $ 4,599 $ 2,051 Amounts billed but unrecognized 2,937 2,390 6,077 3,768 Revenue recognized (2,055) (1,813) (3,695) (3,122) Assumed from business combination — — — 1,407 Balance at end of period $ 6,981 $ 4,104 $ 6,981 $ 4,104 Balance at the end of period (in thousands): June 30, June 30, 2020 2019 Deferred revenue, current $ 5,420 $ 3,467 Deferred revenue, noncurrent 1,561 637 Total deferred revenue $ 6,981 $ 4,104 The activity is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2020 2019 2020 2019 Balance at beginning of period $ 1,730 $ 533 $ 1,152 $ 609 ASC 606 adoption date impact adjustment — — — (222) Amount deferred 398 (9) 1,174 184 Revenue recognized (275) — (473) (2) Payments (211) (50) (211) (95) Balance at end of period $ 1,642 $ 474 $ 1,642 $ 474 Deferred costs and other activity are as follows (in thousands): Three Months Ended June 30, 2020 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Balance at beginning of period $ 29,750 $ 2,868 $ 472 $ 33,090 Additions 14,606 80 96 14,782 Revenue recognized — — (167) (167) Cost of revenue recognized (7,430) — — (7,430) Sales and marketing expenses recognized — (294) — (294) Balance at end of period $ 36,926 $ 2,654 $ 401 $ 39,981 Three Months Ended June 30, 2019 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Balance at beginning of period $ 14,366 $ 3,438 $ 638 $ 18,442 Additions 6,095 184 32 6,311 Revenue recognized — — (250) (250) Cost of revenue recognized (3,350) — — (3,350) Sales and marketing expenses recognized — (257) — (257) Balance at end of period $ 17,111 $ 3,365 $ 420 $ 20,896 Six Months Ended June 30, 2020 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Balance at beginning of period $ 18,579 $ 2,988 $ 184 $ 21,751 Additions 31,750 254 514 32,518 Revenue recognized — — (297) (297) Cost of revenue recognized (13,403) — — (13,403) Sales and marketing expenses recognized — (588) — (588) Balance at end of period $ 36,926 $ 2,654 $ 401 $ 39,981 Six Months Ended June 30, 2019 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Balance at beginning of period $ 8,469 $ — $ — $ 8,469 ASC 606 adoption date impact adjustment — 3,692 771 4,463 Additions 14,590 184 144 14,918 Revenue recognized — — (495) (495) Cost of revenue recognized (5,948) — — (5,948) Sales and marketing expenses recognized $ — $ (511) $ — $ (511) Balance at end of period $ 17,111 $ 3,365 $ 420 $ 20,896 Balance at the end of period (in thousands): June 30, 2020 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Deferred costs, current $ 25,561 $ 1,176 $ 401 $ 27,138 Deferred costs, noncurrent 11,365 1,478 — 12,843 Total deferred costs $ 36,926 $ 2,654 $ 401 $ 39,981 December 31, 2019 Deferred Device Costs Deferred Contract Costs Deferred Execution Credits Total Deferred costs, current $ 14,746 $ 1,121 $ 184 $ 16,051 Deferred costs, noncurrent 3,833 1,867 — 5,700 Total deferred costs $ 18,579 $ 2,988 $ 184 $ 21,751

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Schedule of Allocation of Purchase Consideration	The purchase consideration of $33.5 million was allocated as follows: Amount (in thousands) Cash and cash equivalents $ 2,643 Accounts receivable 1,337 Other current assets 140 Property and equipment 114 Intangible assets 13,900 Other assets 34 Total assets acquired 18,168 Accounts payable 173 Accrued expenses and other liabilities 1,787 Deferred revenue 1,407 Deferred tax liability, net 1,396 Total liabilities assumed 4,763 Goodwill 20,092 Total purchase consideration $ 33,497
Components of Identifiable Intangible Assets Acquired and Their Estimated Useful Lives	The following table sets forth the components of the identifiable intangible assets acquired and their estimated useful lives as of the acquisition date: Cost Useful Life (in thousands) (years) Customer relationships $ 4,300 7.0 Developed technology 9,200 7.0 Trade name 400 5.0 Total $ 13,900
Schedule of Pro Forma Information	The following unaudited pro forma information presents the combined results of operations as if the myStrength Acquisition had been completed on January 1, 2018, the beginning of the comparable prior annual reporting period. The unaudited pro forma results include adjustments primarily related to the following: (i) interest expense related to the legacy debt of myStrength that was not acquired; (ii) amortization of the acquired intangible assets; (iii) fair value adjustment for deferred revenue; (iv) the inclusion of acquisition-related costs as of the earliest period presented; and (v) the associated tax impact of the acquisitions and these unaudited pro forma adjustments. Six Months Ended June 30, 2019 (in thousands) Revenue $ 73,580 Net loss $ (26,009)

Balance Sheet Components - (Tab

Balance Sheet Components - (Tables)	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following: June 30, December 31, 2020 2019 (in thousands) Prepaid expenses $ 5,821 $ 6,691 Escrow deposit, current 3,244 2,100 Interest receivable 1,118 504 Prepaid rent 568 352 Short-term deposits 567 201 Other current assets — 12 Total $ 11,318 $ 9,860
Property and Equipment, Net	Property and equipment consisted of the following: June 30, December 31, 2020 2019 (in thousands) Computer, equipment and software $ 4,618 $ 2,218 Furniture and fixtures 1,971 915 Capitalized internal-use software 13,971 11,229 Leasehold improvements 3,207 1,092 Property and equipment 23,767 15,454 Less: accumulated depreciation (7,558) (5,100) Property and equipment, net $ 16,209 $ 10,354
Schedule of Intangible Assets, Net	Intangible assets consisted of the following as of June 30, 2020: Gross Value Accumulated Net Book Weighted- (in thousands) (years) Customer relationships $ 8,190 $ (1,729) $ 6,461 6.6 Developed technology 11,020 (2,687) 8,333 5.2 Trade name 448 (161) 287 3.6 Total $ 19,658 $ (4,577) $ 15,081 Intangible assets consisted of the following as of December 31, 2019: Gross Value Accumulated Net Book Weighted- (in thousands) (years) Customer relationships $ 8,190 $ (1,227) $ 6,963 7.1 Developed technology 11,020 (1,848) 9,172 5.7 Trade names 448 (114) 334 4.0 Total $ 19,658 $ (3,189) $ 16,469
Finite-lived Intangible Assets Amortization Expense	Amortization expense for intangible assets for the three and six months ended June 30, 2020 and 2019 is as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 (in thousands) Customer relationships $ 251 $ 251 $ 502 $ 418 Developed technology 419 353 839 730 Trade names 22 25 47 45 Total $ 692 $ 629 $ 1,388 $ 1,193
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The expected future amortization expense related to intangible assets as of June 30, 2020 was as follows: Amount (in thousands) Remainder of 2020 $ 1,381 2021 2,762 2022 2,750 2023 2,494 2024 2,324 Thereafter 3,370 Total $ 15,081
Schedule of Noncurrent Other Assets	Other noncurrent assets consisted of the following: June 30, December 31, 2020 2019 (in thousands) Escrow deposit, noncurrent $ — $ 3,150 Other 569 310 Total $ 569 $ 3,460
Schedule of Accrued Liabilities and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: June 30, December 31, 2020 2019 (in thousands) Accrued bonus $ 6,654 $ 8,652 Vendor accruals 4,888 3,984 Contingent consideration, current 2,445 3,004 Accrued commissions 3,827 2,611 Accrued payroll and employee benefits 2,837 2,291 Accrued sales and use taxes 1,043 932 Accrued rebates 1,642 1,152 Employee contribution to ESPP 721 1,805 Accrued Interest 361 — Operating lease liabilities, current 3,130 — Other accrued expenses 8,136 3,370 Total $ 35,684 $ 27,801

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Assets and Liabilities by Level within the Fair Value Hierarchy	The following table sets forth the fair value of our financial assets and liabilities by level within the fair value hierarchy: June 30, 2020 Level 1 Level 2 Level 3 Fair Value (in thousands) Assets Short-term investment: Certificate of deposit 150,000 — — 150,000 Total assets at fair value $ 150,000 $ — $ — $ 150,000 Liabilities Other current liabilities—contingent consideration $ — $ — $ 2,445 $ 2,445 Total liabilities at fair value $ — $ — $ 2,445 $ 2,445 December 31, 2019 Level 1 Level 2 Level 3 Fair Value (in thousands) Assets Cash equivalents: Money market funds $ 130,640 $ — $ — $ 130,640 Short-term investment: Certificate of deposit $ 150,000 $ — $ — $ 150,000 Total assets at fair value $ 280,640 $ — $ — $ 280,640 Liabilities Other current liabilities—contingent consideration $ — $ — $ 3,004 $ 3,004 Other noncurrent liabilities—contingent consideration — — 2,411 2,411 Total liabilities at fair value $ — $ — $ 5,415 $ 5,415
Schedule of Investments Reconciliation	Cash, cash equivalents and short-term investments were as follows (in thousands): June 30, 2020 Adjusted Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Cash $ 685,953 $ — $ — $ 685,953 Money market funds — — $ — — Total cash, and cash equivalents 685,953 — — 685,953 Certificate of deposit 150,000 — — 150,000 Total short-term investments 150,000 — — 150,000 Total cash, cash equivalents and short-term investments $ 835,953 $ — $ — $ 835,953 December 31, 2019 Adjusted Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Cash $ 111,098 $ — $ — $ 111,098 Money market funds 130,640 — — 130,640 Total cash, and cash equivalents 241,738 — — 241,738 Certificate of deposit 150,000 — 150,000 Total short-term investments 150,000 — — 150,000 Total cash, cash equivalents and short-term investments $ 391,738 $ — $ — $ 391,738
Schedule of Changes in Level 3 Financial Liability	The following table sets forth the changes in our contingent consideration liability for the periods presented: Six Months Ended June 30, 2020 2019 (in thousands) Beginning balance $ 5,415 $ 5,004 Contingent consideration recorded upon acquisition (Note 5) — 3,300 Change in fair value of contingent consideration (Note 5) 86 955 Payment related to Retrofit contingent consideration (Note 5) (472) (1,316) Payment related to myStrength contingent consideration (Note 5) (2,584) — Ending balance $ 2,445 7,943

Operating Lease Liabilities (Ta

Operating Lease Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Assets and Liabilities, Lessee	A summary of supplemental lease information is as follows: June 30, 2020 (in thousands) Weighted average remaining lease term (years) 4.5 Weighted average discount rate 3.8 %
Lessee, Operating Lease, Liability, Maturity	Maturities of operating lease liabilities as of June 30, 2020 are as follows: June 30, 2020 (in thousands) Years ending December 31, 2020 (remaining 6 months) $ 2,490 2021 5,094 2022 5,242 2023 5,213 2024 1,799 2025 and thereafter 3,071 Total lease payments 22,909 Less: imputed interest (1,963) Less: tenant allowance (2,058) Total operating lease liabilities $ 18,888 Reported as: Operating lease liabilities, current (1) $ 3,130 Operating lease liabilities, noncurrent 15,758 Total operating lease liabilities $ 18,888 (1) Included as part of "Accrued expenses and other current liabilities" on the condensed consolidated balance sheets. Future minimum lease payments, net of future sublease income of $0.2 million, under operating leases as of December 31, 2019 under ASC 840, the prior lease standard, were as follows: Net Minimum (in thousands) 2020 $ 3,908 2021 5,055 2022 5,233 2023 5,141 2024 1,756 Thereafter 3,068 Total future minimum payments $ 24,161

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule of Shares of Common Stock Reserved for Future Issuance	As of June 30, 2020 and December 31, 2019, we reserved shares of common stock, on an as-if-converted basis, for future issuance as follows: June 30, December 31, 2020 2019 (in thousands) Outstanding warrants to purchase common stock 695 695 Outstanding options to purchase common stock 11,011 14,020 Outstanding restricted stock units 4,785 5,208 Restricted stock awards subject to repurchase 614 736 Estimated shares for future ESPP purchase 1,752 890 Convertible senior notes 7,278 — Available for future issuance under 2019 Plan 11,485 8,160 Total 37,620 29,709

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule of Warrants Outstanding	Common stock warrants outstanding as of June 30, 2020 and December 31, 2019 were as follows: Holder Issue Date Outstanding Exercise Exercisable Expiration (in thousands, except per share data) Partner 3/1/2015 695 $2.28 695 2/28/2025 695 695

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Shares Available for Grant and Stock Option Activity	Stock option activity under the Plans is as follows: Options Outstanding Shares Shares Weighted- Weighted- Aggregate (in thousands, except per share data and years) Balance as of December 31, 2019 8,160 14,020 $ 1.85 6.7 $ 325,474 Shares authorized 3,812 — Exercised — (2,837) $ 1.36 Forfeited/cancelled 172 (172) $ 2.05 Restricted stock units and PSUs granted (1,430) — Restricted stock units and PSUs forfeited 278 — Restricted stock units and PSUs withheld for income taxes 493 — Balance as of June 30, 2020 11,485 11,011 $ 1.97 6.4 $ 806,215 Vested and exercisable as of June 30, 2020 8,221 $ 1.64 6.1 $ 604,619
Schedule of Restricted Stock Awards	Restricted Stock Awards Shares Weighted- (in thousands, except per share data) Unvested balance, December 31, 2019 736 $ 9.76 Vested (122) $ 9.76 Unvested balance, June 30, 2020 614 $ 9.76
Schedule of Restricted Stock Units	Restricted Weighted- (in thousands, except per Balance as of December 31, 2019 4,708 $ 11.31 Granted 1,429 $ 42.48 Released (1,074) $ 9.96 Forfeited (278) $ 12.03 Balance as of June 30, 2020 4,785 $ 13.52
Summary of Stock-Based Compensation Expense	Stock-based compensation expense in the condensed consolidated statements of operations is summarized as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 (in thousands) Cost of revenue $ 118 $ 6 $ 210 12 Research and development expenses 1,593 491 3,809 852 Sales and marketing expenses 2,364 41 4,416 260 General and administrative expenses 5,800 3,915 9,503 8,839 Total stock-based compensation expense $ 9,875 $ 4,453 $ 17,938 $ 9,963

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted net loss per share attributable to our common stockholders: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 (in thousands, except per share data) Net loss $ (1,554) $ (12,977) $ (7,127) $ (27,348) Accretion of redeemable convertible preferred stock — (42) — (83) Net loss attributable to common stockholders $ (1,554) $ (13,019) $ (7,127) $ (27,431) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 97,896 18,916 96,719 18,564 Net loss per share attributable to common stockholders, basic and diluted $ (0.02) $ (0.69) $ (0.07) $ (1.48)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following potential outstanding shares of common stock were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 (in thousands) Redeemable convertible preferred stock — 58,615 — 58,615 Stock options 11,011 15,352 11,011 15,352 Restricted stock awards subject to repurchase 614 736 614 736 Common stock warrants 695 785 695 785 Restricted stock units 4,785 1,207 4,785 1,207 Convertible senior notes 7,278 — 7,278 — ESPP obligations 14 — 14 — Total anti-dilutive shares 24,397 76,695 24,397 76,695

Organization and Description _2

Organization and Description of Business - Narrative (Details)	Jun. 27, 2019	Jul. 31, 2019USD ($)$ / sharesshares	Jun. 30, 2020USD ($)shares	Jun. 30, 2019USD ($)shares	Jun. 30, 2020USD ($)shares	Jun. 30, 2019USD ($)shares	Jun. 04, 2020USD ($)	Mar. 31, 2020shares	Dec. 31, 2019USD ($)shares	Mar. 31, 2019shares	Dec. 31, 2018shares
Class of Stock [Line Items]
Redeemable convertible preferred stock, shares outstanding (in shares) | shares		58,615,488	0	58,615,000	0	58,615,000		0	0	58,615,000	58,615,000
Stock converted		$ 237,000,000
Accumulated deficit			$ (171,325,000)		$ (171,325,000)				$ (164,198,000)
Net loss			(1,554,000)	$ (12,977,000)	(7,127,000)	$ (27,348,000)
Net cash used in operating activities			(3,600,000)	$ (40,000,000)	(3,600,000)	$ (39,961,000)
Convertible Senior Notes Due 2025 | Convertible Debt
Class of Stock [Line Items]
Principal			$ 550,000,000		$ 550,000,000		$ 550,000,000
Interest rate			0.875%		0.875%		0.875%
IPO
Class of Stock [Line Items]
Sale of stock (in shares) | shares		14,590,050
Offering price (in dollars per share) | $ / shares		$ 28
Net proceeds from sale of stock		$ 377,500,000
Underwriting discounts and commissions		28,600,000
Offering expenses		$ 2,400,000
Underwriters' Option
Class of Stock [Line Items]
Sale of stock (in shares) | shares		1,903,050
Common Stock
Class of Stock [Line Items]
Stock converted (in shares) | shares		58,615,488
Reverse stock split conversion ratio	0.5
Redeemable convertible preferred stock
Class of Stock [Line Items]
Reverse stock split conversion ratio	0.5
Additional Paid-in Capital
Class of Stock [Line Items]
Stock converted		$ 236,900,000
Common Stock
Class of Stock [Line Items]
Stock converted		$ 100,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) - USD ($)	Jun. 04, 2020	Sep. 30, 2019	Aug. 07, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Sep. 30, 2019	Dec. 31, 2018	Jan. 01, 2020	Dec. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Sales and marketing				$ 32,881,000	$ 17,833,000	$ 60,535,000	$ 32,476,000
Change in escrow deposit						2,100,000	1,750,000
Payment of deferred acquisition-related contingent consideration						1,356,000	1,316,000
Other comprehensive loss				0	$ 0	0	0
Proceeds from convertible debt						535,225,000	0
Convertible senior notes issuance costs in accounts payable and accrued liabilities						$ 631,000	0
Accounting Standards Update [Extensible List]						us-gaap:AccountingStandardsUpdate201602Member			us-gaap:AccountingStandardsUpdate201409Member
Operating lease right-of-use assets				16,253,000		$ 16,253,000					$ 0
Total operating lease liabilities				18,888,000		18,888,000
Deferred rent											$ 500,000
Net cash used in investing activities						5,156,000	28,691,000
Net cash provided by financing activities						452,971,000	(1,432,000)
Revision of Prior Period, Reclassification, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net cash used in investing activities							1,300,000
Net cash provided by financing activities							$ 1,300,000
Convertible Senior Notes Due 2025 | Convertible Debt
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Principal	$ 550,000,000			$ 550,000,000		$ 550,000,000
Interest rate	0.875%			0.875%		0.875%
Conversion ratio (in shares)	1323.29%
Conversion price (in dollars per share)	$ 75.57			$ 75.57		$ 75.57
Proceeds from convertible debt	$ 534,600,000
Convertible Senior Notes Due 2025 | Convertible Debt | Subsequent Event
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Convertible senior notes issuance costs in accounts payable and accrued liabilities			$ 600,000
Cumulative Effect, Period of Adoption, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Operating lease right-of-use assets										$ 18,100,000
Total operating lease liabilities										$ 18,600,000
Adjustment for Capitalization and Amortization of Sales Commissions
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Sales and marketing								$ (1,200,000)
Increase in Selling and Marketing Expense
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Sales and marketing								400,000
Livongo for Hypertension and Livongo for Prediabetes and Weight Management | Adjustment for Capitalization and Amortization of Device Costs
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Capitalized device costs		$ 1,900,000						$ 1,900,000
Amortization		$ 1,900,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) - Partner Concentration Risk	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Client A | Revenue
Concentration Risk [Line Items]
Concentration risk percentage			25.00%	0.00%	21.00%	0.00%
Client A | Accounts Receivable
Concentration Risk [Line Items]
Concentration risk percentage	12.00%	0.00%
Partner A | Revenue
Concentration Risk [Line Items]
Concentration risk percentage			17.00%	27.00%	20.00%	26.00%
Partner A | Accounts Receivable
Concentration Risk [Line Items]
Concentration risk percentage	17.00%	23.00%
Partner B | Revenue
Concentration Risk [Line Items]
Concentration risk percentage			15.00%	24.00%	16.00%	24.00%
Partner B | Accounts Receivable
Concentration Risk [Line Items]
Concentration risk percentage	21.00%	25.00%

Debt - Narrative (Details)

Debt - Narrative (Details) $ / shares in Units, shares in Millions	Mar. 01, 2025USD ($)	Jun. 04, 2020USD ($)day$ / shares	Aug. 07, 2020USD ($)	Jul. 31, 2019USD ($)	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
Proceeds from convertible debt						$ 535,225,000	$ 0
Convertible senior notes issuance costs in accounts payable and accrued liabilities						631,000	$ 0
Issuance costs					$ 14,775,000	14,775,000
Purchase of capped call related to convertible senior notes					$ 69,850,000	$ 69,850,000
Capped Call Transaction
Debt Instrument [Line Items]
Payments for purchase of capped call		$ 69,900,000
Purchase of capped call related to convertible senior notes		$ 69,900,000
Call Option | Capped Call Transaction
Debt Instrument [Line Items]
Shares available to purchase (in shares) | shares					7.3	7.3
Minimum | Call Option
Debt Instrument [Line Items]
Strike price (in dollars per share) | $ / shares		$ 75.57
Maximum | Call Option
Debt Instrument [Line Items]
Strike price (in dollars per share) | $ / shares		$ 118.54
Convertible Debt | Convertible Senior Notes Due 2025
Debt Instrument [Line Items]
Principal		$ 550,000,000			$ 550,000,000	$ 550,000,000
Conversion ratio		0.0132329
Conversion price (in dollars per share) | $ / shares		$ 75.57			$ 75.57	$ 75.57
Proceeds from convertible debt		$ 534,600,000
Issuance costs		$ 15,400,000
Effective interest rate					7.72%	7.72%
Convertible Debt | Convertible Senior Notes Due 2025 | Level 2
Debt Instrument [Line Items]
Fair value of convertible debt					$ 660,000,000	$ 660,000,000
Convertible Debt | Convertible Senior Notes Due 2025 | Subsequent Event
Debt Instrument [Line Items]
Convertible senior notes issuance costs in accounts payable and accrued liabilities			$ 600,000
Convertible Debt | Convertible Senior Notes Due 2025 | Subsequent Event | Forecast
Debt Instrument [Line Items]
Conversion threshold value	$ 1,000
Convertible Debt | Convertible Senior Notes Due 2025 | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Trading days | day		20
Consecutive trading days | day		30
Percentage of stock price trigger		130.00%
Convertible Debt | Convertible Senior Notes Due 2025 | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Trading days | day		5
Consecutive trading days | day		5
Percentage of stock price trigger		98.00%
Convertible Debt | Convertible Senior Notes Due 2025 | Debt Instrument, Redemption, Period Three
Debt Instrument [Line Items]
Trading days | day		40
Debt redemption price, percentage		100.00%
Convertible Debt | Convertible Senior Notes Due 2025 | Debt Instrument, Redemption, Period Four
Debt Instrument [Line Items]
Trading days | day		20
Consecutive trading days | day		30
Percentage of stock price trigger		130.00%
Debt redemption price, percentage		100.00%
Convertible Debt | Convertible Senior Notes Due 2025, Liability Component
Debt Instrument [Line Items]
Issuance costs		$ 11,400,000
Convertible Debt | Convertible Senior Notes Due 2025, Equity Component
Debt Instrument [Line Items]
Issuance costs		$ 4,000,000
Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Aggregate principal amount of secured revolving loan facility				$ 30,000,000
Floor interest rate				5.25%
Loans outstanding					$ 0	$ 0		$ 0
Revolving Credit Facility | Line of Credit | Prime Rate
Debt Instrument [Line Items]
Floating interest rate				0.25%

Debt - Schedule of Convertible

Debt - Schedule of Convertible Debt (Details) - Convertible Debt $ in Thousands	Jun. 30, 2020USD ($)
Convertible Senior Notes Due 2025
Liability component:
Net carrying amount	$ 574,022
Convertible Senior Notes Due 2025, Liability Component
Liability component:
Principal	550,000
Less: unamortized discount	(142,324)
Less: unamortized issuance costs	(11,230)
Net carrying amount	396,446
Convertible Senior Notes Due 2025, Equity Component
Liability component:
Less: unamortized issuance costs	(4,036)
Equity component:
Notes	144,106
Carrying amount of the equity component	$ 140,070

Debt - Schedule of Interest Exp

Debt - Schedule of Interest Expense (Details) - Convertible Senior Notes Due 2025 - Convertible Debt - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Debt Instrument [Line Items]
Contractual interest expense	$ 361	$ 361
Amortization of Debt Discount (Premium)	1,781	1,781
Amortization of issuance costs	141	141
Total	$ 2,283	$ 2,283

Debt - Schedule of Debt Payment

Debt - Schedule of Debt Payments (Details) - Convertible Debt - Convertible Senior Notes Due 2025 $ in Thousands	Jun. 30, 2020USD ($)
Debt Instrument [Line Items]
Less than 1 Year	$ 4,772
1-3 Years	9,625
3-5 Years	559,625
More than 5 Years	0
Net carrying amount	$ 574,022

Revenue, Deferred Revenue and_2

Revenue, Deferred Revenue and Deferred Costs and Other - Deferred Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Change in Contract with Customer, Liability [Abstract]
Balance at beginning of period	$ 6,099	$ 3,527	$ 4,599	$ 2,051
Amounts billed but unrecognized	2,937	2,390	6,077	3,768
Revenue recognized	(2,055)	(1,813)	(3,695)	(3,122)
Assumed from business combination	0	0	0	1,407
Balance at end of period	6,981	4,104	6,981	4,104
Deferred revenue, current					$ 5,420	$ 3,467
Deferred revenue, noncurrent					1,561	637
Total deferred revenue	$ 6,981	$ 4,104	$ 6,981	$ 4,104	$ 6,981	$ 4,104

Revenue, Deferred Revenue and_3

Revenue, Deferred Revenue and Deferred Costs and Other - Revenue Performance Obligation (Details) $ in Millions	Jun. 30, 2020USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue to be recognized	$ 5.4
Timing for recognition of deferred revenue	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue to be recognized	$ 1.6
Timing for recognition of deferred revenue

Revenue, Deferred Revenue, an_2

Revenue, Deferred Revenue, and Deferred Costs and Other Revenue, Deferred Revenue, and Deferred Costs and Other - Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Accrued rebates	$ 1,642	$ 1,730	$ 1,152	$ 474	$ 533	$ 609

Revenue, Deferred Revenue and_4

Revenue, Deferred Revenue and Deferred Costs and Other - Accrued Rebates (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jan. 01, 2019
Change In Accrued Rebate [Roll Forward]
Balance at beginning of period	$ 1,730	$ 533	$ 1,152	$ 609
ASC 606 adoption date impact adjustment	1,642	474	1,642	474
Amount deferred	398	(9)	1,174	184
Revenue recognized	(275)	0	(473)	(2)
Payments	(211)	(50)	(211)	(95)
Balance at end of period	$ 1,642	$ 474	$ 1,642	$ 474
Impact of Adoption | ASC 606
Change In Accrued Rebate [Roll Forward]
ASC 606 adoption date impact adjustment					$ (222)

Revenue, Deferred Revenue and_5

Revenue, Deferred Revenue and Deferred Costs and Other - Deferred Costs and Other (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Dec. 31, 2019	Jan. 01, 2019
Change in Contract with Customer, Asset [Abstract]
Balance at beginning of period	$ 33,090	$ 18,442	$ 21,751	$ 8,469
ASC 606 adoption date impact adjustment	39,981	20,896	21,751	8,469	$ 39,981	$ 21,751
Additions	14,782	6,311	32,518	14,918
Revenue recognized	(167)	(250)	(297)	(495)
Cost of revenue recognized	(7,430)	(3,350)	(13,403)	(5,948)
Sales and marketing expenses recognized	(294)	(257)	(588)	(511)
Balance at end of period	39,981	20,896	39,981	20,896
Deferred costs, current					27,138	16,051
Deferred costs, noncurrent					12,843	5,700
Total deferred costs	39,981	20,896	21,751	8,469	39,981	21,751
Deferred Device Costs
Change in Contract with Customer, Asset [Abstract]
Balance at beginning of period	29,750	14,366	18,579	8,469
ASC 606 adoption date impact adjustment	36,926	17,111	36,926	8,469	36,926	18,579
Additions	14,606	6,095	31,750	14,590
Revenue recognized	0	0	0	0
Cost of revenue recognized	(7,430)	(3,350)	(13,403)	(5,948)
Sales and marketing expenses recognized	0	0	0	0
Balance at end of period	36,926	17,111	36,926	17,111
Deferred costs, current					25,561	14,746
Deferred costs, noncurrent					11,365	3,833
Total deferred costs	36,926	17,111	36,926	8,469	36,926	18,579
Deferred Contract Costs
Change in Contract with Customer, Asset [Abstract]
Balance at beginning of period	2,868	3,438	2,988	0
ASC 606 adoption date impact adjustment	2,654	3,365	2,654	0	2,654	2,988
Additions	80	184	254	184
Revenue recognized	0	0	0	0
Cost of revenue recognized	0	0	0	0
Sales and marketing expenses recognized	(294)	(257)	(588)	(511)
Balance at end of period	2,654	3,365	2,654	3,365
Deferred costs, current					1,176	1,121
Deferred costs, noncurrent					1,478	1,867
Total deferred costs	2,654	3,365	2,654	0	2,654	2,988
Deferred Execution Credits
Change in Contract with Customer, Asset [Abstract]
Balance at beginning of period	472	638	184	0
ASC 606 adoption date impact adjustment	401	420	184	0	401	184
Additions	96	32	514	144
Revenue recognized	(167)	(250)	(297)	(495)
Cost of revenue recognized	0	0	0	0
Sales and marketing expenses recognized	0	0	0	0
Balance at end of period	401	420	401	420
Deferred costs, current					401	184
Deferred costs, noncurrent					0	0
Total deferred costs	$ 401	$ 420	$ 184	$ 0	$ 401	$ 184
Impact of Adoption | ASC 606
Change in Contract with Customer, Asset [Abstract]
ASC 606 adoption date impact adjustment							$ 4,463
Total deferred costs							4,463
Impact of Adoption | ASC 606 | Deferred Device Costs
Change in Contract with Customer, Asset [Abstract]
ASC 606 adoption date impact adjustment							0
Total deferred costs							0
Impact of Adoption | ASC 606 | Deferred Contract Costs
Change in Contract with Customer, Asset [Abstract]
ASC 606 adoption date impact adjustment							3,692
Total deferred costs							3,692
Impact of Adoption | ASC 606 | Deferred Execution Credits
Change in Contract with Customer, Asset [Abstract]
ASC 606 adoption date impact adjustment							771
Total deferred costs							$ 771

Business Combinations - Narrati

Business Combinations - Narrative (Details) - USD ($)	1 Months Ended						3 Months Ended			6 Months Ended
	Jun. 30, 2020	Feb. 28, 2020	Dec. 31, 2019	Apr. 30, 2019	Feb. 28, 2019	Apr. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Business Acquisition [Line Items]
Increase (decrease) in fair value of contingent consideration							$ 2,000	$ 282,000		$ 86,000	$ 956,000
Payment of deferred acquisition-related contingent consideration										1,356,000	1,316,000
Retrofit
Business Acquisition [Line Items]
Total purchase consideration paid in cash						$ 12,400,000
Earn-out consideration obligated to pay (up to)						7,000,000
Escrow asset						7,000,000
Fair value of contingent consideration						6,200,000
Total purchase consideration						$ 18,600,000
Escrow deposit disbursements	$ 2,100,000			$ 1,800,000
Contingent consideration	2,400,000		$ 2,800,000				$ 2,400,000			$ 2,400,000
myStrength
Business Acquisition [Line Items]
Total purchase consideration paid in cash					$ 30,100,000
Earn-out consideration obligated to pay (up to)					5,000,000
Fair value of contingent consideration					3,300,000
Total purchase consideration					33,500,000
Increase (decrease) in fair value of contingent consideration								600,000			1,200,000
Closing adjustment					$ 100,000
Payment of deferred acquisition-related contingent consideration		$ 2,600,000	$ 2,400,000
Acquisition-related costs									$ 200,000
Former Retrofit Stockholders | Retrofit
Business Acquisition [Line Items]
Escrow deposit disbursements	$ 500,000			$ 1,300,000
Maximum | Retrofit
Business Acquisition [Line Items]
Increase (decrease) in fair value of contingent consideration								$ 300,000			$ 300,000

Business Combinations - Schedul

Business Combinations - Schedule of Allocation of Purchase Consideration (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Feb. 28, 2019
Business Acquisition [Line Items]
Goodwill	$ 35,801	$ 35,801
myStrength
Business Acquisition [Line Items]
Cash and cash equivalents			$ 2,643
Accounts receivable			1,337
Other current assets			140
Property and equipment			114
Acquired intangible assets			13,900
Other assets			34
Total assets acquired			18,168
Accounts payable			173
Accrued expenses and other liabilities			1,787
Deferred revenue			1,407
Deferred tax liability, net			1,396
Liabilities assumed			4,763
Goodwill			20,092
Total purchase consideration			$ 33,497

Business Combinations - Compone

Business Combinations - Components of Identifiable Intangible Assets Acquired and Their Estimated Useful Lives (Details) - myStrength $ in Thousands	1 Months Ended
	Feb. 28, 2019USD ($)
Business Acquisition [Line Items]
Cost	$ 13,900
Customer relationships
Business Acquisition [Line Items]
Cost	$ 4,300
Useful Life	7 years
Developed technology
Business Acquisition [Line Items]
Cost	$ 9,200
Useful Life	7 years
Trade name
Business Acquisition [Line Items]
Cost	$ 400
Useful Life	5 years

Business Combinations - Sched_2

Business Combinations - Schedule of Pro Forma Information (Details) - myStrength $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Business Acquisition [Line Items]
Revenue	$ 73,580
Net loss	$ (26,009)

Balance Sheet Components - Inve

Balance Sheet Components - Inventories (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Finished goods	$ 17.6	$ 29

Balance Sheet Components - Prep

Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid expenses	$ 5,821	$ 6,691
Escrow deposit, current	3,244	2,100
Interest receivable	1,118	504
Prepaid rent	568	352
Short-term deposits	567	201
Other current assets	0	12
Total	$ 11,318	$ 9,860

Balance Sheet Components - Prop

Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment	$ 23,767		$ 23,767		$ 15,454
Less: accumulated depreciation	(7,558)		(7,558)		(5,100)
Property and equipment, net	16,209		16,209		10,354
Depreciation and amortization expense	1,400	$ 700	2,619	$ 1,450
Computer, equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment	4,618		4,618		2,218
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment	1,971		1,971		915
Capitalized internal-use software
Property, Plant and Equipment [Line Items]
Property and equipment	13,971		13,971		11,229
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment	$ 3,207		$ 3,207		$ 1,092

Balance Sheet Components - Inta

Balance Sheet Components - Intangible Assets, Net (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross Value		$ 19,658	$ 19,658
Accumulated Amortization		(4,577)	(3,189)
Net Book Value		15,081	16,469
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Value		8,190	8,190
Accumulated Amortization		(1,729)	(1,227)
Net Book Value		6,461	6,963
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Value		11,020	11,020
Accumulated Amortization		(2,687)	(1,848)
Net Book Value		8,333	9,172
Trade name
Finite-Lived Intangible Assets [Line Items]
Gross Value		448	448
Accumulated Amortization		(161)	(114)
Net Book Value		$ 287	$ 334
Weighted Average | Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life	7 years 1 month 6 days	6 years 7 months 6 days
Weighted Average | Developed technology
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life	5 years 8 months 12 days	5 years 2 months 12 days
Weighted Average | Trade name
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life	4 years	3 years 7 months 6 days

Balance Sheet Components - In_2

Balance Sheet Components - Intangible Asset Amortization Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 692	$ 629	$ 1,388	$ 1,193
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	251	251	502	418
Developed technology
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	419	353	839	730
Trade name
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 22	$ 25	$ 47	$ 45

Balance Sheet Components - Futu

Balance Sheet Components - Future Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remainder of 2020	$ 1,381
2021	2,762
2022	2,750
2023	2,494
2024	2,324
Thereafter	3,370
Net Book Value	$ 15,081	$ 16,469

Balance Sheet Components - Good

Balance Sheet Components - Goodwill (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Goodwill	$ 35,801,000	$ 35,801,000
Goodwill impairment	$ 0

Balance Sheet Components - Othe

Balance Sheet Components - Other Noncurrent Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Escrow deposit, noncurrent	$ 0	$ 3,150
Other	569	310
Total	$ 569	$ 3,460

Balance Sheet Components - Accr

Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued bonus	$ 6,654	$ 8,652
Vendor accruals	4,888	3,984
Contingent consideration, current	2,445	3,004
Accrued commissions	3,827	2,611
Accrued payroll and employee benefits	2,837	2,291
Accrued sales and use taxes	1,043	932
Accrued rebates	1,642	1,152
Employee contribution to ESPP	721	1,805
Accrued Interest	361	0
Operating lease liabilities, current	3,130	0
Other accrued expenses	8,136	3,370
Total	$ 35,684	$ 27,801

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Financial Assets and Liabilities by Level within the Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Assets
Cash equivalents and short-term investments	$ 685,953	$ 241,738
Liabilities
Other current liabilities—contingent consideration	2,445	3,004
Fair Value, Recurring
Assets
Total assets at fair value	150,000	280,640
Liabilities
Other current liabilities—contingent consideration	2,445	3,004
Other noncurrent liabilities—contingent consideration		2,411
Total liabilities at fair value	2,445	5,415
Fair Value, Recurring | Level 1
Assets
Total assets at fair value	150,000	280,640
Liabilities
Other current liabilities—contingent consideration	0	0
Other noncurrent liabilities—contingent consideration		0
Total liabilities at fair value	0	0
Fair Value, Recurring | Level 2
Assets
Total assets at fair value	0	0
Liabilities
Other current liabilities—contingent consideration	0	0
Other noncurrent liabilities—contingent consideration		0
Total liabilities at fair value	0	0
Fair Value, Recurring | Level 3
Assets
Total assets at fair value	0	0
Liabilities
Other current liabilities—contingent consideration	2,445	3,004
Other noncurrent liabilities—contingent consideration		2,411
Total liabilities at fair value	2,445	5,415
Money Market Funds [Member]
Assets
Cash equivalents and short-term investments	0	130,640
Money Market Funds [Member] | Fair Value, Recurring
Assets
Cash equivalents and short-term investments		130,640
Money Market Funds [Member] | Fair Value, Recurring | Level 1
Assets
Cash equivalents and short-term investments		130,640
Money Market Funds [Member] | Fair Value, Recurring | Level 2
Assets
Cash equivalents and short-term investments		0
Money Market Funds [Member] | Fair Value, Recurring | Level 3
Assets
Cash equivalents and short-term investments		0
Certificate of deposit | Fair Value, Recurring
Assets
Cash equivalents and short-term investments	150,000	150,000
Certificate of deposit | Fair Value, Recurring | Level 1
Assets
Cash equivalents and short-term investments	150,000	150,000
Certificate of deposit | Fair Value, Recurring | Level 2
Assets
Cash equivalents and short-term investments	0	0
Certificate of deposit | Fair Value, Recurring | Level 3
Assets
Cash equivalents and short-term investments	$ 0	$ 0

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Unrealized Gains (Losses) (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Adjusted Amortized Cost
Cash and cash equivalents	$ 685,953	$ 241,738	$ 38,165
Certificate of deposit	150,000	150,000
Total cash, cash equivalents and short-term investments	835,953	391,738
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value
Cash equivalents and cash equivalents, fair value	685,953	241,738
Total cash, and cash equivalents	150,000	150,000
Total cash, cash equivalents and short-term investments	835,953	391,738
Cash
Adjusted Amortized Cost
Cash and cash equivalents	685,953	111,098
Fair Value
Cash equivalents and cash equivalents, fair value	685,953	111,098
Money Market Funds [Member]
Adjusted Amortized Cost
Cash and cash equivalents	0	130,640
Fair Value
Cash equivalents and cash equivalents, fair value	0	130,640
Certificate of deposit
Adjusted Amortized Cost
Certificate of deposit	150,000	150,000
Gross Unrealized Gains	0
Gross Unrealized Losses	0	0
Fair Value
Total cash, and cash equivalents	$ 150,000	$ 150,000

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) $ in Thousands	Jun. 30, 2020USD ($)	Dec. 31, 2019USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2018USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration liability	$ 2,445	$ 5,415	$ 7,943	$ 5,004
Measurement Input, Revenue Volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability, measurement input	0.0510
Measurement Input, Revenue Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability, measurement input	0.006
Measurement Input, Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability, measurement input	0.0017

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Changes in Level 3 Financial Liability (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 5,415	$ 5,004
Contingent consideration recorded upon acquisition (Note 5)	0	3,300
Change in fair value of contingent consideration (Note 5)	86	955
Ending balance	2,445	7,943
Retrofit
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Payment related to contingent consideration	(472)	(1,316)
myStrength
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Payment related to contingent consideration	$ (2,584)	$ 0

Operating Lease Liabilities - N

Operating Lease Liabilities - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Operating lease cost	$ 0.9		$ 1.9
Variable lease cost	$ 0.1		$ 0.3
Rent expense		$ 0.6		$ 1.2
Future sublease income receivable					$ 0.2
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease term	3 years		3 years
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term	7 years		7 years

Operating Lease Liabilities - S

Operating Lease Liabilities - Supplemental Lease Information (Details)	Jun. 30, 2020
Leases [Abstract]
Weighted average remaining lease term (years)	4 years 6 months
Weighted average discount rate	3.80%

Operating Lease Liabilities - O

Operating Lease Liabilities - Operating Lease Maturity (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Operating Leases After Adoption
2020 (remaining 6 months)	$ 2,490
2021	5,094
2022	5,242
2023	5,213
2024	1,799
2025 and thereafter	3,071
Total lease payments	22,909
Less: imputed interest	(1,963)
Less: tenant allowance	(2,058)
Total operating lease liabilities	18,888
Operating lease liabilities, current	3,130	$ 0
Operating lease liabilities, noncurrent	15,758	0
Total operating lease liabilities	$ 18,888
Operating Leases Before Adoption
2020		3,908
2021		5,055
2022		5,233
2023		5,141
2024		1,756
Thereafter		3,068
Total future minimum payments		$ 24,161

Stockholders_ Equity - Narrativ

Stockholders’ Equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Dec. 31, 2019	Jul. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Class of Stock [Line Items]
Stock converted		$ 237,000
Preferred stock, shares issued (in shares)	0		0		0
Preferred stock, shares outstanding (in shares)	0		0		0
Accretion to redemption price of redeemable convertible preferred stock (less than for the three months ended June 30, 2019)			$ 0	$ 42	$ 0	$ 83
Preferred stock, shares authorized (in shares)	100,000,000	100,000,000	100,000,000		100,000,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001		$ 0.001
Common stock, shares authorized (in shares)	900,000,000	900,000,000	900,000,000		900,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001		$ 0.001
IPO
Class of Stock [Line Items]
Sale of stock (in shares)		14,590,050
Offering price (in dollars per share)		$ 28
Net proceeds from sale of stock		$ 377,500
Underwriting discounts and commissions		28,600
Offering expenses		$ 2,400
Underwriters' Option
Class of Stock [Line Items]
Sale of stock (in shares)		1,903,050
Common Stock
Class of Stock [Line Items]
Stock converted (in shares)		58,615,488
Common Stock | Secondary Offering - Shares From Existing Shareholders [Member]
Class of Stock [Line Items]
Sale of stock (in shares)	2,777,327
Offering price (in dollars per share)	$ 27
Maximum
Class of Stock [Line Items]
Accretion to redemption price of redeemable convertible preferred stock (less than for the three months ended June 30, 2019)				$ 100		$ 100

Stockholders_ Equity - Schedule

Stockholders’ Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details) - shares shares in Thousands	Jun. 30, 2020	Dec. 31, 2019
Class of Stock [Line Items]
Total	37,620	29,709
Convertible Senior Notes Due 2025
Class of Stock [Line Items]
Total	7,278	0
Outstanding options to purchase common stock
Class of Stock [Line Items]
Total	11,011	14,020
Outstanding restricted stock units
Class of Stock [Line Items]
Total	4,785	5,208
Restricted stock awards subject to repurchase
Class of Stock [Line Items]
Total	614	736
Estimated shares for future ESPP purchase
Class of Stock [Line Items]
Total	1,752	890
Available for future issuance under 2019 Plan
Class of Stock [Line Items]
Total	11,485	8,160
Outstanding warrants to purchase common stock
Class of Stock [Line Items]
Total	695	695

Common Stock Warrants - Schedul

Common Stock Warrants - Schedule of Warrants Outstanding (Details) - $ / shares shares in Thousands	Jun. 30, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Outstanding shares (in shares)	695	695
Exercisable shares (in shares)	695	695
Warrants Expiring Feb 2025
Class of Warrant or Right [Line Items]
Outstanding shares (in shares)	695	695
Exercise price (in dollars per share)	$ 2.28	$ 2.28
Exercisable shares (in shares)	695	695

Common Stock Warrants - Narrati

Common Stock Warrants - Narrative (Details)	6 Months Ended
	Jun. 30, 2020shares
Equity [Abstract]
Warrants exercised (in shares)	0

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($)	1 Months Ended					3 Months Ended		6 Months Ended
	Mar. 31, 2020	Jul. 31, 2019	Apr. 30, 2019	Mar. 31, 2019	Jan. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)						37,620,000		37,620,000		29,709,000
Aggregate intrinsic value of stock option awards exercised						$ 74,700,000	$ 23,900,000	$ 105,900,000	$ 28,100,000
Options granted (in shares)						0	0	0	0
Unrecognized compensation expense						$ 82,800,000		$ 82,800,000
Unrecognized compensation expense, recognition period								3 years 6 months
Stock-based compensation expense						9,875,000	$ 4,453,000	$ 17,938,000	$ 9,963,000
Stock-based compensation related to capitalized internal-use software (less than)						$ 200,000		$ 300,000
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)						614,000		614,000		736,000
Unrecognized compensation expense						$ 4,500,000		$ 4,500,000
Unrecognized compensation expense, recognition period								2 years 2 months 12 days
Number of awards granted (in shares)				982,301
Stock-based compensation expense						500,000	2,900,000	$ 1,000,000	3,100,000
Grant date fair value of awards issued				$ 9,600,000
Vested (in shares)								122,000
Restricted Stock Units, Performance RSUs and PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards granted (in shares)								1,429,000
Stock-based compensation expense						100,000		$ 200,000
Vested (in shares)								1,074,000
Service-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards granted (in shares)					982,301
Stock-based compensation expense						500,000	500,000	$ 900,000	900,000
Vesting period								4 years
Service-Based RSUs | Vesting Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period								4 years
Vesting percentage								25.00%
Service-Based RSUs | Vesting Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period								4 years
Vesting percentage								2.08%
Performance-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards granted (in shares)			100,000					23,196
Vesting period			4 years					1 year
Performance-Based RSUs | Vesting Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period								6 months 1 day
RSUs and Performance RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense						$ 4,500,000	3,600,000	$ 10,600,000	7,000,000
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)						4,785,000		4,785,000		5,208,000
Number of awards granted (in shares)								1,430,000
Stock-based compensation expense								$ 3,800,000
Vested (in shares)					491,151
Service and Market-Based Options and RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense						$ 1,200,000		$ 1,200,000
Unrecognized compensation expense, recognition period								2 years 2 months 12 days
Stock-based compensation expense						$ 200,000	200,000	$ 400,000	600,000
Service and Market-Based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options canceled (in shares)				196,460
Service and Market-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards granted (in shares)					161,250
Canceled Market-based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense									200,000
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)						1,752,000		1,752,000		890,000
Unrecognized compensation expense						$ 700,000		$ 700,000
Unrecognized compensation expense, recognition period								1 month 6 days
Stock-based compensation expense						$ 400,000		$ 900,000
Stock-based compensation expense (in shares)								90,613
RSUs Vested And Released [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares immediately vested in award modification (in shares)	11,412
Stock-based compensation expense recognized due to immediate vested in award modification	$ 100,000
2019 Employee Incentive Plan, Transferred From 2014 and 2008 Stock Incentive Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)		21,770,029
2019 Employee Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)		8,004,000
Annual increase in capital shares reserved for future issuance (in shares)		7,120,000
Percentage of outstanding stock maximum		4.00%
2019 Employee Stock Purchase Plan | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)		890,000
Annual increase in capital shares reserved for future issuance (in shares)		2,670,000
Percentage of outstanding stock maximum		1.00%
Maximum payroll deduction		15.00%
Purchase price of common stock (percent)		85.00%
Maximum number of shares per employee (in shares)		500
Maximum value per employee		$ 12,500
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation related to capitalized internal-use software (less than)							$ 100,000		$ 100,000
Maximum | 2019 Employee Stock Purchase Plan | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ownership percentage threshold to participate		5.00%

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Shares Available for Grant and Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	Dec. 31, 2019	Apr. 30, 2019	Jun. 30, 2020
Shares Available for Grant
Balance as of December 31, 2019 (in shares)			8,160,000
Shares authorized (in shares)			3,812,000
Forfeited/cancelled (in shares)			172,000
Balance as of June 30, 2020 (in shares)	8,160,000		11,485,000
Shares Subject to Options Outstanding
Balance as of December 31, 2019 (in shares)			14,020,000
Exercised (in shares)			(2,837,000)
Forfeited/cancelled (in shares)			(172,000)
Balance as of June 30, 2020 (in shares)	14,020,000		11,011,000
Options vested and exercisable as of June 30, 2020 (in shares)			8,221,000
Weighted- Average Exercise Price
Balance as of December 31, 2019 (in USD per share)			$ 1.85
Exercised (in USD per share)			1.36
Forfeited/cancelled (in USD per share)			2.05
Balance as of June 30, 2020 (in USD per share)	$ 1.85		1.97
Options vested and exercisable as of June 30, 2019 (in USD per share)			$ 1.64
Weighted- Average Remaining Contractual Life (Years) and Aggregate Intrinsic Value
Weighted- Average Remaining Contractual Life (Years), Options outstanding	6 years 8 months 12 days		6 years 4 months 24 days
Weighted- Average Remaining Contractual Life (Years), Options vested and exercisable			6 years 1 month 6 days
Aggregate Intrinsic Value, Options outstanding	$ 325,474		$ 806,215
Aggregate Intrinsic Value, Options vested and exercisable			$ 604,619
Restricted stock units
Shares Available for Grant
Granted (in shares)			(1,430,000)
Performance-Based RSUs
Shares Available for Grant
Granted (in shares)		(100,000)	(23,196)
Forfeited (in shares)			278,000
Performance stock units
Shares Available for Grant
Forfeited (in shares)			493,000

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Restricted Stock Awards (Details) - Restricted Stock Awards shares in Thousands	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Shares
Unvested balance, December 31, 2019 (in shares) | shares	736
Vested (in shares) | shares	(122)
Unvested balance, June 30, 2020 (in shares) | shares	614
Weighted- Average Grant Date Fair Value
Unvested balance, December 31, 2019 (in USD per share) | $ / shares	$ 9.76
Vested (in USD per share) | $ / shares	9.76
Unvested balance, June 30, 2020 (in USD per share) | $ / shares	$ 9.76

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Restricted Stock Units (Details) - Restricted Stock Units, Performance RSUs and PSUs shares in Thousands	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Shares
Unvested balance, December 31, 2019 (in shares) | shares	4,708
Issued (in shares) | shares	1,429
Vested (in shares) | shares	(1,074)
Forfeited (in shares) | shares	(278)
Unvested balance, June 30, 2020 (in shares) | shares	4,785
Weighted- Average Grant Date Fair Value
Unvested balance, December 31, 2019 (in USD per share) | $ / shares	$ 11.31
Issued (in USD per share) | $ / shares	42.48
Vested (in USD per share) | $ / shares	9.96
Forfeited (in USD per share) | $ / shares	12.03
Unvested balance, June 30, 2020 (in USD per share) | $ / shares	$ 13.52

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 9,875	$ 4,453	$ 17,938	$ 9,963
Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	118	6	210	12
Research and development expenses
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	1,593	491	3,809	852
Sales and marketing expenses
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	2,364	41	4,416	260
General and administrative expenses
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 5,800	$ 3,915	$ 9,503	$ 8,839

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income tax benefit	$ (72)	$ (5)	$ (93)	$ 1,383

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Schedule of Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Earnings Per Share [Abstract]
Net loss	$ (1,554)	$ (12,977)	$ (7,127)	$ (27,348)
Accretion of redeemable convertible preferred stock	0	(42)	0	(83)
Net loss attributable to common stockholders	$ (1,554)	$ (13,019)	$ (7,127)	$ (27,431)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares)	97,896	18,916	96,719	18,564
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.02)	$ (0.69)	$ (0.07)	$ (1.48)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	24,397	76,695	24,397	76,695
Redeemable convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	0	58,615	0	58,615
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	11,011	15,352	11,011	15,352
Restricted stock awards subject to repurchase
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	614	736	614	736
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	695	785	695	785
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	4,785	1,207	4,785	1,207
Convertible senior notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	7,278	0	7,278	0
ESPP obligations
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	14	0	14	0

Net Loss Per Share Attributab_5

Net Loss Per Share Attributable to Common Stockholders - Narrative (Details) - $ / shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 04, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	24,397	76,695	24,397	76,695
Convertible senior notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential outstanding shares of common stock excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	7,278	0	7,278	0
Convertible Senior Notes Due 2025 | Convertible Debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Conversion price (in dollars per share)	$ 75.57		$ 75.57		$ 75.57

Segment Information (Details)

Segment Information (Details)	6 Months Ended
	Jun. 30, 2020segment
Segment Reporting [Abstract]
Number of operating segments	1

Related Party Transactions (Det

Related Party Transactions (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Service Provider Fees | Affiliated Entity
Related Party Transaction [Line Items]
Related party fees	$ 100

Employee Benefits (Details)

Employee Benefits (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Retirement Benefits [Abstract]
Plan expenses	$ 0.2	$ 0.3	$ 0.9	$ 0.6

Subsequent Event - Narrative (D

Subsequent Event - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	Aug. 05, 2020	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019	Jul. 31, 2019
Subsequent Event [Line Items]
Common stock, par value (in dollars per share)			$ 0.001	$ 0.001	$ 0.001
Subsequent Event
Subsequent Event [Line Items]
Common stock, par value (in dollars per share)	$ 0.001
Subsequent Event | Teladoc Health, Inc
Subsequent Event [Line Items]
Common stock, par value (in dollars per share)	0.001
Subsequent Event | Teledoc Merger
Subsequent Event [Line Items]
Cash paid (in dollars per share)	$ 4.24
Subsequent Event | Teledoc Merger | Common Stock
Subsequent Event [Line Items]
Share exchange ratio (in shares)	0.5920
Subsequent Event | Forecast | Teledoc Merger
Subsequent Event [Line Items]
Special cash dividend (in dollars per share)		$ 7.09
Merger termination fee		$ 562,810